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Abstract
Background
Dementia is a progressive global cognitive impairment syndrome. In 2010, more than 35 million people worldwide were
estimated to be living with dementia. Some people with mild cognitive impairment (MCI) will progress to dementia but others
remain stable or recover full function. There is great interest in finding good predictors of dementia in people with MCI. The
Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an
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overall measure of cognitive impairment in clinical, research and community settings.
Objectives
To determine the diagnostic accuracy of the MMSE at various thresholds for detecting individuals with baseline MCI who
would clinically convert to dementia in general, Alzheimer’s disease dementia or other forms of dementia at follow-up.
Search methods
We searched ALOIS (Cochrane Dementia and Cognitive Improvement Specialized Register of diagnostic and intervention
studies (inception to May 2014); MEDLINE (OvidSP) (1946 to May 2014); EMBASE (OvidSP) (1980 to May 2014); BIOSIS
(Web of Science) (inception to May 2014); Web of Science Core Collection, including the Conference Proceedings Citation
Index (ISI Web of Science) (inception to May 2014); PsycINFO (OvidSP) (inception to May 2014), and LILACS (BIREME)
(1982 to May 2014). We also searched specialized sources of diagnostic test accuracy studies and reviews, most recently in
May 2014: MEDION (Universities of Maastricht and Leuven, www.mediondatabase.nl), DARE (Database of Abstracts of
Reviews of Effects, via the Cochrane Library), HTA Database (Health Technology Assessment Database, via the Cochrane
Library), and ARIF (University of Birmingham, UK, www.arif.bham.ac.uk). No language or date restrictions were applied to
the electronic searches and methodological filters were not used as a method to restrict the search overall so as to maximize
sensitivity. We also checked reference lists of relevant studies and reviews, tracked citations in Scopus and Science Citation
Index, used searches of known relevant studies in PubMed to track related articles, and contacted research groups
conducting work on MMSE for dementia diagnosis to try to locate possibly relevant but unpublished data.
Selection criteria
We considered longitudinal studies in which results of the MMSE administered to MCI participants at baseline were obtained
and the reference standard was obtained by follow-up over time. We included participants recruited and clinically classified
as individuals with MCI under Petersen and revised Petersen criteria, Matthews criteria, or a Clinical Dementia Rating = 0.5.
We used acceptable and commonly used reference standards for dementia in general, Alzheimer’s dementia, Lewy body
dementia, vascular dementia and frontotemporal dementia.
Data collection and analysis
We screened all titles generated by the electronic database searches. Two review authors independently assessed the
abstracts of all potentially relevant studies. We assessed the identified full papers for eligibility and extracted data to create
two by two tables for dementia in general and other dementias. Two authors independently performed quality assessment
using the QUADAS-2 tool. Due to high heterogeneity and scarcity of data, we derived estimates of sensitivity at fixed values
of specificity from the model we fitted to produce the summary receiver operating characteristic curve.
Main results
In this review, we included 11 heterogeneous studies with a total number of 1569 MCI patients followed for conversion to
dementia. Four studies assessed the role of baseline scores of the MMSE in conversion from MCI to all-cause dementia and
eight studies assessed this test in conversion from MCI to Alzheimer´s disease dementia. Only one study provided
information about the MMSE and conversion from MCI to vascular dementia. For conversion from MCI to dementia in
general, the accuracy of baseline MMSE scores ranged from sensitivities of 23% to 76% and specificities from 40% to 94%.
In relationship to conversion from MCI to Alzheimer’s disease dementia, the accuracy of baseline MMSE scores ranged from
sensitivities of 27% to 89% and specificities from 32% to 90%. Only one study provided information about conversion from
MCI to vascular dementia, presenting a sensitivity of 36% and a specificity of 80% with an incidence of vascular dementia of
6.2%. Although we had planned to explore possible sources of heterogeneity, this was not undertaken due to the scarcity of
studies included in our analysis.
Authors' conclusions
Our review did not find evidence supporting a substantial role of MMSE as a stand-alone single-administration test in the
identification of MCI patients who could develop dementia. Clinicians could prefer to request additional and extensive tests to
be sure about the management of these patients. An important aspect to assess in future updates is if conversion to
dementia from MCI stages could be predicted better by MMSE changes over time instead of single measurements. It is also
important to assess if a set of tests, rather than an isolated one, may be more successful in predicting conversion from MCI
to dementia.
Plain language summary
Baseline scores of Mini-Mental State examination (MMSE) for early prediction of developing dementia in
people with mild cognitive impairments (MCI)
Patients with MCI should be evaluated and monitored due to their increased risk of progression to dementia. At present there
are no agreements about what the best approach is to register the progression to dementia. Several cognitive function tests
have been proposed for this task because most of them are easy to administer, take no longer than 10 minutes to complete,
involve major executive functions, and yield an objective score. Our review assessed the current evidence related to one of
those brief tests, the Mini-Mental State Examination (MMSE), in the prediction of decline to dementia in people with cognitive
impairments. After an extensive search and analysis of available information, we did not find evidence supporting a
substantial role of MMSE as a stand-alone single-administration test in the identification of patients who will convert to
dementia in the future.
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Background 
Dementia is a progressive global cognitive impairment syndrome. In 2010, more than 35 million people worldwide were
estimated to be living with dementia, a number that will increase to more than 115 million by 2050 (Ferri 2005; Prince 2013; 
Wimo 2010). Dementia encompasses a group of neurodegenerative disorders that are characterised by progressive
loss of both cognitive function and the ability to perform daily living activities. It can be accompanied by neuropsychiatric
symptoms and challenging behaviours of varying type and severity. Its underlying pathology is usually degenerative,
and subtypes of dementia include Alzheimer’s disease dementia (ADD), vascular dementia, dementia with Lewy bodies
and frontotemporal dementia, among others. Considerable overlap may be noted in the clinical and pathological
presentations of dementia (MRC CFAS 2001), and ADD and vascular dementia often coexist (Matthews 2009; Savva 2009).
Recently a new type of cognitive function stage called mild cognitive impairment (MCI) has been proposed. MCI
refers to a heterogeneous condition and currently 16 different classifications are used to define it (Matthews 2008; Petersen
1999; Petersen 2004; Winblad 2004). Prevalence of MCI varies widely (between 0.1% and 42%) according to the
criteria applied, with most systems including memory impairment and absence of cognitive decline as basic
conditions for diagnosis (Stephan 2007). As part of the Aging, Demographics, and Memory Study (ADAMS)
assessment, Plassman et al estimated the prevalence of cognitive impairment without dementia as 22% in people
aged 71 years or older (Plassman 2008). MCI may be classified as amnestic or non-amnestic, according to the
presence of clinically significant memory impairment that does not meet the criteria for dementia, or a subtle decline
in other functions not related to memory (Petersen 2011).
Over time, people with MCI may experience a gradually progressive cognitive decline and changes in personality
and behaviour. When the cognitive impairment in memory, reasoning, language and visuospatial abilities interferes
with daily function, individuals are diagnosed with dementia. Research studies indicate that an annual average of
10% to 15% of individuals with MCI may progress to dementia, in particular ADD, but with wide variation depending
upon the source of study participants, with self-selected clinic attendees having the highest conversion rates (Bruscoli 2004; 
Mitchell 2008). Information on long-term cohorts suggests that annual conversion rates range from 4.2% (95%
confidence interval (CI) 3.9% to 4.6%) for all-cause dementia to 5.8% (95% CI 5.5% to 6.5%) for ADD (Mitchell 2008).
Establishing a definitive diagnosis of MCI in the presence of subtle symptoms can be challenging. In these cases, it
is necessary to document the cognitive decline from the patient's medical history and corroborate it by means of
neuropsychological testing, among other suggested tools (Petersen 2001). The American Academy of Neurology
recommended in 2001 that patients with MCI should be evaluated and monitored in accordance with their risk of
progression to dementia by means of general or brief cognitive screening tools (Petersen 2001). Likewise, the National
Institute on Aging and the Alzheimer's Association remarked in 2011 that longitudinal evidence of progressive decline
in cognition could support the diagnosis of MCI due to ADD and could allow assessment of the potential benefits of
early treatment (Albert 2011).
Usually recognition and assessment of people with suspected dementia in any setting (community, primary care or
secondary care) requires a brief test of cognitive function or the use of informant questionnaires, or both (Arevalo-Rodriguez
2013; Moyer 2014). The brief cognitive evaluations needed are usually paper-and-pencil tests that are easy to
administer, take no longer than 10 minutes to complete, involve major executive functions and yield an objective
score. This final score is useful in determining which individuals need a more comprehensive evaluation (usually
identified by low scores) (Boustani 2003). One of these brief cognitive tests is the Mini-Mental State Examination
(MMSE) (Folstein 1975), which has become the best-known and the most often used short screening tool for
providing an overall measure of cognitive impairment in clinical, research and community settings, although it is
now the subject of copyright issues (Nieuwenhuis-Mark 2010).
Systematic assessments of the diagnostic accuracy of brief cognitive tests such as MMSE are scarce (Arevalo-Rodriguez
2014). In 1992, Tombaugh et al presented a narrative review of MMSE studies that emphasised psychometric
properties such as reliability and construct validity without evaluating the quality of the included evidence (Tombaugh 1992
). Later, Mitchell published a meta-analysis of cross-sectional studies of MMSE and reported different estimations of
sensitivity and specificity according to the setting and population (Mitchell 2009). Until now, the relationship between MMSE
scores and conversion from MCI to ADD or other dementias has not been evaluated in a systematic fashion.
It is thus the aim of this DTA review for diagnostic test accuracy in dementia to evaluate the ability of the MMSE in such
settings as community residences, primary care facilities and memory clinics to identify those people with MCI who will
progress to the full clinical syndrome of dementia.
Target condition being diagnosed
In general, dementia as diagnosed is defined by a deficit in more than two cognitive domains that is of sufficient
degree to impair functional activities. Symptoms are usually progressive over a period of at least several months
and should not be attributable to any other brain disease (American Psychiatric Association 1994). Dementia develops
over a trajectory of several years, and it is presumed that during some portion of this time people are asymptomatic and
pathology is accumulating (Jack 2011). Individuals or their relatives may notice subtle impairments of recent
memory during this time. Gradually, more cognitive domains become involved and difficulty planning complex tasks
becomes increasingly apparent. Subtypes of dementia include Alzheimer's disease dementia (ADD) (McKhann 1984; 
McKhann 2011), vascular dementia (Roman 1993), frontotemporal dementia (Lund and Manchester Groups 1994)
and Lewy body dementia (McKeith 1996), among others. Some dementia subtypes are related to other neurological
diseases such as Parkinson's disease (Goetz 2008).
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This review focused on conversion from MCI to all-cause dementia, ADD, as well as conversion from MCI to other
forms of dementia, which were assessed at follow-up. As was previously noted, several studies have shown that
most patients with MCI are at increased risk of developing dementia (Petersen 2011). Several medications have been
evaluated for use in reducing or delaying the risk of progression, but none have been adopted for extended clinical use
(Farina 2012; Russ 2012; Yue 2012).
Index test(s)
The Folstein Mini-Mental State Examination (MMSE) is a 30-question assessment of cognitive function that
evaluates attention and orientation, memory, registration, recall, calculation, language and ability to draw a complex
polygon (Folstein 1975). The MMSE has recently been subject to copyright restrictions (de Silva 2010). In its inception, the
MMSE was not conceived to identify early stages of dementia, distinguish between different types of dementia or to predict
the development of dementia in the long term.
Advantages of the MMSE include rapid administration, availability of multiple language translations and high
levels of acceptance as a diagnostic instrument amongst health professionals and researchers (Nieuwenhuis-Mark 2010
). The presence of cognitive decline is determined by the total score. Traditionally, a 23/24 cut-off has been used
to select patients with suspected cognitive impairment or dementia (Tombaugh 1992). However, several studies
have shown that sociocultural variables, age and education, among other factors, could affect individual scores (Bleecker
1988; Brayne 1990; Crum 1993); therefore local standards must be developed for each population and setting
evaluated (Diniz 2007; Kulisevsky 2009; Shiroky 2007; Trenkle 2007).
Clinical Pathway 
Dementia develops over a trajectory of several years. It is presumed that during some portion of this time people are
asymptomatic and pathology is accumulating. Individuals or their relatives may notice subtle impairments of recent
memory during this time. Gradually, more cognitive domains become involved and difficulty planning complex tasks
becomes increasingly apparent. People with memory complaints usually present to their general practitioner (primary
care), who may administer one or more brief cognitive tests and potentially refer the individual to a memory clinic
(secondary care). However, many people with dementia do not present until much later in the course of the disease
and follow a different pathway to diagnosis. In community settings, screening tests are usually administered to
estimate the epidemiological figures of dementia, identify cases to be included in clinical trials or even establish a
follow-up to detect incident cases or changes in cognitive performance (Brayne 2011). In all cases, a follow-up period is
mandatory to detect cognitive changes in populations and conversion of mild cases to dementia (delayed verification).
Standard assessment of dementia includes a history and clinical examination (including neurological, mental state and
cognitive examinations); laboratory tests such as thyroid-stimulating hormone, serum folic acid, serum vitamin B12
and blood count; an interview with a relative or other informant; and neuroradiological evaluation (Feldman 2008; Hort 2010
). Before dementia is diagnosed, other physical and mental disorders (for example hypothyroidism, depression) that
might be contributing to cognitive impairment should be excluded or treated. Neuropsychological examination
includes full assessment of major cognitive domains, including memory, executive functions, language, attention
and visuospatial skills. A neuroradiological examination (computed tomography (CT) or magnetic resonance
imaging (MRI) scan of the brain) is also recommended in most recent consensus guidelines (McKhann 2011),
although the use of cerebrospinal fluid (CSF) biomarkers is controversial (Dubois 2010). Sometimes the diagnosis is made
on the basis of history and presentation alone.
Prior test(s)
Most tests (for example neuroimaging, CSF analysis) are usually performed after a cognitive deficit has been identified.
However, it is conceivable that patients with abnormalities on brain imaging, performed for any number of reasons, are likely
to be tested subsequently for cognitive deficits.
Role of index test(s)
Accurate diagnosis leads to opportunities for treatment. At the present time, no 'cure' for dementia is known but some
treatments can slow cognitive and functional decline or reduce associated behavioural and psychiatric symptoms of
dementia (Birks 2006; Clare 2003; McShane 2006). Furthermore, diagnosis of ADD (and other dementias) at an early stage
will help people with dementia, their families and potential carers in making timely plans for the future. Coupled with
appropriate contingency planning, proper recognition of the disease may help to prevent inappropriate and potentially
harmful admissions to hospital or institutional care. In addition, accurate early identification of dementia may increase
opportunities for the use of newly evolving interventions designed to delay or prevent progression to more debilitating stages
of dementia.
Alternative test(s)
The Cochrane Dementia and Cognitive Improvement Group is undertaking a series of DTA systematic reviews,
including a full investigation of other short cognitive tests like the Montreal Cognitive Assessment (Davis 2013a) and the
Mini-Cog test (Chan 2014; Fage 2013; Seitz 2014).
Rationale
The public health burden of cognitive and functional impairment due to dementia is of growing concern. With the
changing age structure of populations in both high- and low-income countries, the prevalence of dementia is increasing (
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Ferri 2005; Prince 2013). At the population level, this has major implications for service provision and planning given that the
condition leads to progressive functional dependence over several years. Accurate diagnosis leads to opportunities for
treatment and appropriate care, but it is also crucial to identify participants for clinical trials of sufficient power to demonstrate
the effectiveness of potential treatments.
At the present time, no 'cure' for dementia is known, but some treatments can slow cognitive and functional decline or
reduce associated behavioural and psychiatric symptoms of dementia (Birks 2006; Clare 2003; McShane 2006).
Furthermore, diagnosis of ADD (and other dementias) at an early stage (that is MCI) will help people with dementia, their
families and potential carers in making timely plans for the future. Coupled with appropriate contingency planning, proper
recognition of the disease may help prevent inappropriate and potentially harmful admissions to hospital or institutional care.
In addition, accurate early identification of dementia may increase opportunities for the use of newly evolving interventions
designed to delay or prevent progression to more debilitating stages of disease.
The Cochrane Dementia and Cognitive Improvement Group is undertaking a series of DTA systematic reviews, including
three on the accuracy of the MMSE for diagnosing dementia. This review will be focused on evaluation of the MMSE and
delayed-verification studies for assessment of conversion from MCI to dementia.
Objectives 
To determine the diagnostic accuracy of the MMSE at various thresholds for detecting individuals with MCI at baseline who
would clinically convert to all-cause dementia, Alzheimer’s disease dementia or other forms of dementia at follow-up.
Secondary objectives
To assess the heterogeneity of test accuracy by population (for example memory clinics, community settings) and MMSE
thresholds, amongst other factors.
Methods 
Criteria for considering studies for this review
Types of studies 
We considered longitudinal studies in which results of the MMSE administered to MCI participants were obtained at baseline
and the reference standard was obtained by follow-up over time (at least 12 months). We excluded cross-sectional studies,
before-after studies and case reports.
Participants
We included participants recruited from community, primary care and secondary care settings and clinically
classified as individuals with MCI at baseline. We established the diagnosis of MCI using Petersen and revised
Petersen criteria (Petersen 1999; Petersen 2004), Matthews criteria (Matthews 2008) or Clinical Dementia Rating
(CDR) = 0.5 (Morris 1993). These criteria include subjective complaints, decline in memory objectively verified by
neuropsychological testing in combination with patient history, decline in other cognitive domains, minimal or no impairment
in activities of daily living and not meeting the criteria for dementia. We included all subtypes of MCI participants (amnestic
single domain, amnestic multiple domain, non-amnestic single domain and non-amnestic multiple domain). We excluded
studies of participants with a secondary cause of cognitive impairment, namely current or past alcohol or drug abuse, central
nervous system (CNS) trauma (for example subdural haematoma), tumour and infection, amongst others.
Index tests
The Mini-Mental State Examination (Folstein 1975), or MMSE, is a simple pen-and-paper test of cognitive function based on
a total possible score of 30 points; it includes tests of orientation, concentration, attention, verbal memory, naming and
visuospatial skills. In follow-up studies, participants with MCI are evaluated by the MMSE to obtain a baseline score and then
are followed for several months to allow identification of new cases of dementia. Its utility as a predictive factor could be
evaluated for several thresholds, some of them previously specified or otherwise obtained from statistical methods (for
example logistic regression); optimal cut-offs are established according to sensitivity and specificity figures, amongst others.
Target conditions
The target condition was conversion at follow-up from MCI to all-cause dementia, Alzheimer's disease dementia (ADD) or
other forms of dementia. We expected to find most studies focused on ADD, vascular dementia, Lewy body dementia and
frontotemporal dementia.
Reference standards
Currently, no in vivo gold standard is used for the diagnosis of dementia, and even the value of diagnoses based
on neuropathological criteria has been questioned (Scheltens 2011). However, we used acceptable and commonly
used reference standards. Clinical diagnosis after follow-up includes all-cause (unspecified) dementia, according to
recognised diagnostic criteria for example the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) and the International Classification of Diseases, 10th Revision (ICD-10). National Institute of Neurological
and Communicative Disorders and Stroke (NINCDS)-Alzheimer Disease and Related Disorders Association
(ADRDA) criteria (McKhann 1984; McKhann 2011) are the best antemortem clinical consensus gold standard for
ADD, defining three antemortem groups: probable, possible and unlikely ADD. DSM and ICD definitions are also
acceptable classifications for diagnosis of eventual ADD. The reference standard for Lewy body dementia was the
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McKeith criteria (McKeith 1996; McKeith 2005), for frontotemporal dementia the Lund-Manchester criteria (Lund and
Manchester Groups 1994) and for vascular dementia the National Institute of Neurological Disorders and Stroke
(NINDS)-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN) criteria (Roman 1993).
Search methods for identification of studies 
Electronic searches 
We searched ALOIS (Cochrane Dementia and Cognitive Improvement Specialized Register of diagnostic and intervention
studies (inception to May 2014), MEDLINE (OvidSP) (1946 to May 2014), EMBASE (OvidSP) (1980 to May 2014), BIOSIS
(Web of Science) (inception to May 2014), Web of Science Core Collection including the Conference Proceedings Citation
Index (ISI Web of Science) (inception to May 2014), PsycINFO (OvidSP) (inception to May 2014) and LILACS (BIREME)
(1982 to May 2014). We identified grey literature in the form of conference abstracts in a number of our database searches,
especially in EMBASE and the Web of Science Core Collection, which includes the Conference Proceedings Citation Index.
We designed similarly structured search strategies using search terms appropriate for each database (see Appendix 1
for all the search strategies). We used standardized database subject headings such as MeSH terms (in MEDLINE)
and Emtree (in EMBASE) and other standardized headings (controlled vocabulary) in other databases, as
appropriate. We did not use search filters designed to retrieve diagnostic test accuracy studies (collections of terms
aimed at reducing the number needed to screen by filtering out irrelevant records and retaining only those that are
relevant) as a method to restrict the search overall because available filters have not yet proved sensitive enough for
systematic review searches (Whiting 2011). We did not apply any language restriction to the electronic searches. We
requested a search of the Cochrane Register of Diagnostic Test Accuracy Studies (hosted and maintained by the Cochrane
Renal Group) and the specialised register of the Cochrane Dementia and Cognitive Improvement Group, ALOIS, which
includes both intervention and diagnostic test accuracy studies in dementia. A single researcher with extensive experience of
systematic reviewing performed the initial searches.
Searching other resources 
We checked the reference lists of all relevant papers for additional studies. We also searched:
MEDION database (Meta-analyses van Diagnostisch Onderzoek), www.mediondatabase.nl;
DARE (Database of Abstracts of Reviews of Effects), http://www.crd.york.ac.uk/CRDWeb/;
HTA Database (Health Technology Assessment Database, the Cochrane Library),
ARIF database (Aggressive Research Intelligence Facility), www.arif.bham.ac.uk.
Through PubMed, relevant studies were used to search for additional studies using the 'Related Articles' feature. We
tracked key studies in citation databases such as the Science Citation Index and Scopus to ascertain further
relevant studies. We identified grey literature in the form of conference abstracts in a number of our database
searches, especially in EMBASE and the Web of Science Core Collection, which includes the Conference
Proceedings Citation Index. We also attempted to contact researchers involved in studies with possibly relevant but
unpublished data. We did not perform handsearching as the evidence for the benefits of handsearching is not
certain. The findings of a recent study investigating handsearching as a method for identifying diagnostic test
accuracy studies suggested little additional benefit for handsearching above a robust initial search strategy in a well-
indexed and clearly defined subject area (Glanville 2012).
Data collection and analysis 
Selection of studies 
We selected studies on the basis of title and abstract screening undertaken by the review authors or by teams of
experienced assessors. We then located the full paper for each potentially eligible study identified by the search, and two
review authors independently evaluated each study for inclusion or exclusion. We resolved disagreements by discussion. If
this did not prove conclusive, the default position was to include the study. We presented the study selection process in a
PRISMA flow diagram.
Data extraction and management
We extracted data on study characteristics into a study-specific proforma and included data on assessment of quality and
investigation of heterogeneity, as described in Appendix 2. The proforma was piloted against five primary diagnostic studies.
Two review authors extracted data. We cross-tabulated in 2 × 2 tables the index test results (positive or negative) against the
target disorder (positive or negative) and showed results in RevMan tables.
Assessment of methodological quality
We assessed the methodological quality of each study by using the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) (Whiting 2011a), as recommended by The Cochrane Collaboration. This tool is made up of four
domains: patient selection, index test, reference standard and patient flow (see Appendix 3). Each domain was assessed in
terms of risk of bias, and the first three domains were also considered in terms of applicability. We reported the QUADAS-2
methodological assessment of studies using bespoke tables. Operational definitions describing the use of QUADAS-2 are
detailed in Appendix 4.
Statistical analysis and data synthesis
The target condition comprised two categories: (1) all-cause dementia (not otherwise specified) and (2) dementia subtypes
(Alzheimer’s, vascular, Lewy body, etc.). Studies may detail one or both outcomes. Each of these target conditions deserved
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a separate meta-analysis.
For all included studies, the data in the 2 × 2 tables (showing binary test results cross-classified with the binary reference
standard) were used to calculate sensitivities and specificities, with their 95% confidence intervals. We presented individual
study results graphically by plotting estimates of sensitivities and specificities both in a forest plot and in a receiver operating
characteristic (ROC) space. We considered these findings in the light of the previous systematic assessment (using
QUADAS-2) of the methodological quality of individual studies. We used RevMan software to document these descriptive
analyses. When more than one threshold were reported in an individual study, we presented the graphical findings for all
thresholds reported.
Meta-analyses was performed with the metandi command in Stata, version 13 (StataCorp, College Station, Texas)
that estimates the parameters for bivariate random-effects models (Leeflang 2008; Reitsma 2005). If no covariates
are included in the model, a function of the parameter estimates for the bivariate model allows one to obtain the
parameters of the equivalent hierarchical summary ROC model (HSROC) (Harbord 2007). The HSROC model's
parameters were used to plot the ROC curve in RevMan. For descriptive purposes, and due to the considerable
uncertainty regarding the pooled results, we expressed our results in absolute terms by estimating the diagnostic
accuracy of the index test in an hypothetical cohort of 100 MCI patients, using the median specificity and estimating
the corresponding sensitivity according to the HSROC model's parameters. This approach has been used in previous
diagnostic test accuracy (DTA) Cochrane reviews about dementia (Ritchie 2014; Zhang 2014).
Investigations of heterogeneity
In preliminary analyses, we visually examined forest plots of sensitivity and specificity and summary ROC (SROC) plots to
explore the effect of the sources of heterogeneity. We had planned to explore potential sources of heterogeneity across
studies through meta-regression, by fitting HSROC models with several pre-specified covariates in SAS. However, there
were insufficient studies to conduct a formal investigation of heterogeneity as planned.
Sensitivity analyses
Due to the limited number of studies evaluating MMSE for all-cause dementia, we performed sensitivity analyses
only for studies of ADD regarding the version of MMSE test used. This was different to the protocol (Arevalo-Rodriguez
2013a) and is explained in the Differences between protocol and review section.
Assessment of reporting bias
Quantitative methods for exploring reporting bias are not well established for studies of DTA. Specifically, we did not consider
funnel plots of the diagnostic odds ratio (DOR) versus the standard error of this estimate.
Results 
Results of the search
Our search resulted in 24,357 citations (47 identified in congress reports), of which 17,513 references that were not
related to MMSE information were excluded (Figure 1). After that, 6844 records were screened by the authors; excluding
6611 citations. Then 233 records were assessed in more depth in order to apply the inclusion criteria; 186 studies were
excluded as they did not include participants with MCI at baseline, and did not assess the conversion from MCI to dementia.
Finally, 47 references were retrieved in full text. The review team excluded 35 of them, mainly because they did not provide
data about the accuracy of MMSE for conversion to dementia from MCI (see Characteristics of excluded studies). We
contacted nine authors to request useable data, of which six responded. Two studies with insufficient data were therefore
excluded (Li 2011; Mauri 2012). One study retrieved in abstract form was classified as an 'ongoing study' because the
authors presented a protocol in progress but without information about the accuracy of MMSE scores (Hall 2012).
The review included 12 references representing 11 datasets with a total of 1569 participants (Summary of findings table 2).
Methodological quality of included studies
We assessed the risk of bias using the QUADAS-2 tool (Appendix 3; Appendix 4). The main results are summarized
below (Figure 2; Figure 3).
In the patient selection domain we judged three studies (Conde-Sala 2012; Meguro 2007a; Meguro 2007b) to be at
high risk of bias due to poor reporting of both the sampling procedure and exclusion criteria. We considered four
studies (Buchhave 2008; Chopard 2009; Modrego 2005; Palmqvist 2012) to be at unclear risk of bias because they
did not report whether the participants were systematically enrolled. We considered the remaining four studies (Devanand
2008; Modrego 2013; Pozueta 2011; Xu 2002) to be at low risk of bias. We stated that all included studies avoided a case-
control design because we only considered data on the performance of the index test to discriminate between patients with
MCI who converted to dementia and those who remained stable (that is delayed verification cohort studies).
In the index test domain we considered eight studies (Buchhave 2008; Chopard 2009; Devanand 2008; Modrego 2005; 
Modrego 2013; Palmqvist 2012; Pozueta 2011; Xu 2002) to be at high risk of bias because the threshold used was
not pre-specified and the optimal cut-off level was determined from ROC analyses; therefore, the accuracy of the
MMSE reported in these studies appeared to be overestimated. Some studies reported poorly which MMSE version
was used and who administered and interpreted the test. We judged the remaining three studies (Conde-Sala 2012; Meguro
2007a; Meguro 2007b) to be at low risk of bias.
In the references´ standard domain we considered four studies (Buchhave 2008; Conde-Sala 2012; Modrego 2013; Xu 2002
) to be at 'unclear' risk of bias and two more at high risk (Modrego 2005; Pozueta 2011) because they did not provide enough
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information about independence and blinding between baseline MMSE scores and the final diagnosis of dementia. These
last studies also did not provide enough information about the criteria to establish the conversion from MCI to dementia at
follow-up.
In the flow and timing domain we considered the majority of studies (eight) to be at low risk of bias. We judged two
(Devanand 2008; Pozueta 2011) to be at high risk of bias and one (Modrego 2005) to be at unclear risk of bias due to loss to
follow-up (5% to 15% of losses at follow-up) or poor reporting, or both.
For assessment of applicability concerns, for the majority of the studies (seven) there was no concern that the included
patients and setting, the conduct and interpretation of the index test, and the target condition (as defined by the reference
standard) did not match the review question. We judged that there was unclear concern about applicability for Modrego 2005
regarding all three domains and for Buchhave 2008, Modrego 2013 and Pozueta 2011 regarding the reference standard
domain. It should be noted that the lack of concern about applicability of the three domains mentioned above was based on
the inclusion criteria set in the review.
Findings
Included studies are detailed in Characteristics of included studies and Summary of findings table 2 and Summary of
findings table 3. The total number of participants across all included studies was 1569 (median = 109; inter-quartile
range (IQR) = 105 to 140). The maximum percentage of losses to follow-up was 15% (Devanand 2008).
One of the references (Meguro 2007a; Meguro 2007b) contained two independent datasets with different follow-ups
and we included these as separate entries. Another reference had a single population followed in two different time
frames and thresholds (Modrego 2005). We included the information from the longest follow-up (three years) in
general analysis. Finally, one of the studies showed information about the accuracy of the Orientation and Recall
MMSE subscales (Palmqvist 2012) but this information was not included in our analysis.
More than half of the studies were developed with patients from memory clinics (Buchhave 2008; Chopard 2009; Conde-
Sala 2012; Devanand 2008; Palmqvist 2012; Pozueta 2011) with average ages greater than 60 years. In all studies, between
36.3% and 70% of participants were women. Few studies provided descriptive information about social class, years of
education, MMSE version used, comorbidities or APOE-ε4 status. No study provided information about pharmacological or
non-pharmacological interventions for MCI during the follow-up.
Four different diagnostic thresholds were used to define a positive MMSE (≤ 21, ≤ 26, ≤ 28, ≤ 29). Two additional
datasets (Meguro 2007a and Meguro 2007b) considered cut-offs according to individual years of education (≤ 17
for less or equal to 6 years of education, ≤ 20 for 7 to 8 years of education, and ≤ 23 for 10 or more years of
education). One additional study provided accuracy for a predicted risk of 0.5 derived from a univariate logistic
regression model, instead of a MMSE threshold (Devanand 2008).
Average follow-up times ranged from 15 months to seven years. Median incidence of all-cause dementia in general was
36.5% (4 datasets; IQR = 32.9 to 37.8), while the median incidence of ADD was 39.4% (8 datasets; IQR = 13.3 to 54.2).
Only one study provided data for vascular dementia (VaD) incidence (Xu 2002, 6.26%). The scope of the studies
included data from five different countries: four studies from Spain; two from Japan, Switzerland and USA; and one
from France. In general, sensitivity and specificity figures ranged between 23% and 88% and 32% and 94%,
respectively (Summary of findings table 3).
Baseline MMSE scores for conversion from MCI to all-cause dementia
Three studies provided numerical data for conversion from MCI to all-cause dementia, with four datasets (n = 792).
Sensitivity ranged from 23% to 76% and specificity ranged from 40% to 94% (Figure 4). Figure 5 shows the accuracy
estimations of included studies in ROC space along with the SROC curve fitted by the model. We noticed a large lack of
precision represented by the 95% confidence interval around the pooled estimates as well as a wide region of prediction,
showing a high degree of influence of heterogeneity in this analysis. Under these conditions, there was considerable
uncertainty regarding the combination of results from these studies, and the pooled results derived from this model need to
be interpreted with caution. The degree of heterogeneity as well as the quality of evidence lowers the level of confidence in
the strength of the results. To translate the meta-analysis results into absolute effects, at the median specificity of 88%, we
estimated the sensitivity to be 40%. In a hypothetical cohort of 100 MCI patients with a 36.5% incidence of dementia, the
number of missed cases would be 18 patients, while 8 MCI patients would be overdiagnosed.
Baseline MMSE scores for conversion from MCI to Alzheimer's disease dementia (ADD)
Eight studies provided numerical data for conversion from MCI to ADD (n = 1128). Sensitivity ranged from 27% to 89%
and specificity ranged from 32% to 90% (Figure 6). Figure 7 shows the accuracy estimates of included studies in ROC space
along with the SROC curve fitted by the model. Again, we noticed a high lack of precision represented by the 95%
confidence intervals around the pooled estimations as well as a wide region of prediction, showing the large influence of
heterogeneity in this analysis. For example, the study of Conde-Sala 2012 (outside the estimated curve) was very different to
the rest of studies with its sensitivity and specificity (44% and 45%, respectively) and its cut-off for ADD (21/22 points). Under
these conditions, there was considerable uncertainty regarding the combination of results from these studies, and the pooled
results derived from this model need to be interpreted with caution. The degree of heterogeneity as well as the quality of
evidence lowered our confidence in the strength of the results. To obtain absolute effects, at the median specificity of 80%,
the estimated sensitivity was 54%. In a hypothetical cohort of 100 MCI patients with a 39.2% incidence of ADD the number of
missed cases would be 18 patients, and 12 MCI patients would be overdiagnosed.
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Baseline MMSE scores for conversion from MCI to vascular dementia (VaD)
Only one study provided information about conversion from MCI to VaD (Xu 2002). This study presented a sensitivity of 36%
and a specificity of 80% with an incidence of VaD of 6.2%. In a hypothetical cohort of 100 MCI patients the number of missed
cases would be 5 patients, and 19 MCI patients would be overdiagnosed.
Analysis of heterogeneity and sensitivity analysis
Although we had planned to explore possible sources of heterogeneity through meta-regression, including several pre-
specified variables, this was not undertaken due to the scarcity of studies included in our meta-analysis. In a narrative
description, we noticed that the index test threshold was one of the main sources of variability between included studies.
Only five studies (two for conversion to all-cause dementia, three for conversion to ADD and one for conversion to VaD)
shared a common threshold (26/27 points), the remaining studies used other cut-offs to classify converters.
We also noticed an important variability in the estimated incidence of dementia. For instance, the incidence for ADD varied
between 13% and 54% in MCI samples analysed. The influence of factors such as training of evaluators, education,
presence of APOE-4 or onset of medical management was not assessed due to lack of reporting of these variables in the
included studies. Related to version of MMSE used, we performed a sensitivity analysis for conversion from MCI to ADD. We
removed the data of Modrego 2005 and Modrego 2013 because these studies used a MMSE version with a different scale
(35 points). We did not find a significant difference in test accuracy or in perception of heterogeneity when these studies were
removed.
Given the modest number of papers and the clinical heterogeneity registered, we did not perform any further sensitivity
analysis by risk of bias measured with QUADAS-II items.
Discussion 
Summary of main results
In this review we included 11 heterogeneous studies with a total number of 1569 MCI patients followed for conversion to
dementia. Four studies assessed the role of baseline scores of MMSE in conversion from MCI to all-cause dementia (defined
by the authors of each study) and eight studies assessed this test in conversion from MCI to Alzheimer´s disease dementia
(ADD). Only one study provided information about MMSE and conversion from MCI to vascular dementia (VaD). Other
dementias, such as frontotemporal dementia or Lewy body dementia, were not assessed by any study. Due to the high
heterogeneity and the scarcity of data we could not formally evaluate the influence of factors such as the threshold, the
follow-up times, or even the incidence of dementia in the accuracy of this test.
For conversion from MCI to all-cause dementia, we included information from 792 patients (Chopard 2009; Meguro 2007a; 
Modrego 2005; Xu 2002), 255 of whom developed dementia. Two out of four included studies used CDR scores of
0.5 as the definition of cognitive impairment without dementia. The follow-up time frames were wider in comparison
with the rest of studies included in this review (from 14 months to 7 years). Only two studies shared a common cut-off
to define dementia (scores ≤ 26) and showed higher specificities and lower sensitivities in comparison with the rest of
studies in this group. The accuracy of baseline MMSE scores ranged from sensitivities of 23% (Meguro 2007b) to
76% (Chopard 2009) and specificities from 40% (Chopard 2009) to 94% (Meguro 2007a). We obtained a summary sensitivity
of 40% from the SROC curve at the median specificity of 88%. According to this information, MMSE scores appear to have a
modest specificity but without the capacity to detect more than half of the MCI converters.
Related to conversion from MCI to ADD, we included information from 1128 patients (Buchhave 2008; Conde-Sala 2012; 
Devanand 2008; Modrego 2005; Modrego 2013; Palmqvist 2012; Pozueta 2011; Xu 2002) 374 of whom developed
ADD. Five out of eight included studies used the Petersen diagnostic criteria (Petersen 1999; Petersen 2004) for
defining MCI. The follow-up times in this group of studies were between two and six years. Only three studies (Modrego
2005; Pozueta 2011; Xu 2002) shared a common threshold (scores ≤ 26). The accuracy of baseline MMSE scores
ranged from sensitivities of 27% (Devanand 2008) to 89% (Buchhave 2008) and specificities from 32% (Buchhave 2008
) to 90% (Devanand 2008). We obtained a summary sensitivity of 54% from the SROC curve at the median specificity of
80%. Again, MMSE scores appear to have a modest specificity but without the capacity to detect near to half of MCI-
converters.
Strengths and weaknesses of the review
Our review is part of a series of diagnostic test accuracy (DTA) reviews related to neuropsychological tests on
dementia, for which a generic protocol was developed. This protocol identified a priori the best methodology in order to
assess the accuracy of cognitive tests in the identification or conversion to any type of dementia (Davis 2013).
This review is the first Cochrane DTA review to assess the role of a well-known paper-and-pencil test (MMSE) in the
evaluation of people in the early dementia stage, an entity recently recognized as an important frontier for successful
management of this condition. We were challenged in the selection of studies for the research question because we shared a
search strategy designed to cover all the DTA reviews related to MMSE and its accuracy in different settings (that is in
people over 65 years within a secondary healthcare setting, and asymptomatic and previously clinically unevaluated people
aged over 65 years in community and primary care populations). At the same time, with the use of such an exhaustive
search strategy we could be sure we included all possible studies, even those with smaller sample sizes, to determine the
accuracy of MMSE in predicting conversion from MCI to full dementia.
Although the MMSE is a cognitive test with more than 40 years of use, we only identified studies published since 2002 to
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answer our research question, possibly due to our specific baseline population (MCI). Also, the review only included studies
with a delayed verification of the diagnosis, in contrast to the classic cross-sectional assessment of test accuracy. Such a
combination of inclusion criteria had a direct influence on the number of retrieved and included studies in our review. For
instance, a considerable number of studies with potential information were excluded because MMSE scores were evaluated
as a part of prediction models without providing information about the accuracy of a specified threshold. We hope that in the
future we can update our review with information provided by the contacted authors of excluded studies as well as ongoing
studies.
We noticed that most of the included studies did not have the assessment of baseline MMSE scores as a main purpose. In
most studies the MMSE was included as part of the usual diagnostic pathway for MCI patients and a common comparator for
the principal test assessed. This directly affected the reporting quality and, most importantly, the methodological evaluation of
included studies. Our results showed that the index test domain had the greater risk of bias, in most of the cases due to lack
of reporting related to administration of MMSE as well as the absence of pre-specified thresholds. We think that the lack of
pre-specified thresholds partially explained the high level of heterogeneity among the included studies. The scarcity of
information did not allow us to formally assess the influence of this factor in the accuracy of MMSE, but the differences are
easily noticed in the analysis of SROC curves. Additional factors that could affect the operative characteristics of MMSE,
such as APOE status, the duration of MCI stage at the beginning of the study or even the administration of pharmacological
or non-pharmacological interventions were not reported in a consistent way to be considered in our analyses.
Applicability of findings to the review question
Although the MMSE is a test with quick and easy administration, needs few resources and covers multiple cognitive
domains at once, it is necessary to remark that this test was not developed to identify the early stages of dementia
or even to predict the development of dementia in the long term. In our review, although it was not possible to
estimate in a valid way the pooled operating characteristics, the descriptive data provided by the studies showed
that neither the sensitivity nor specificity exceeded 80% at the same time. Only one study (Modrego 2005) shows a balance
between accuracy figures, estimating a sensitivity of 76% and a specificity of 67% for the conversion of MCI to ADD, but
derived from information with a high risk of bias. Our results suggest that MMSE may be of value to decrease the post-test
probability of progression to dementia in the presence of normal test scores that confirm the possible conversion. These
results may show that the items of the MMSE are insufficient to detect the change from mild to advanced cognitive decline,
or even that some factors such as age, education and literacy must be taken into account to determine its true value in MCI
patients. Likewise, this brief cognitive test may be more useful to document cognitive changes over time rather than to
predict future progression with a single measurement. The verification of this hypothesis requires the assessment of
evidence not presented in this review.
Authors' conclusions 
Implications for practice 
At present, there is consensus about the clinical relevance of MCI because this stage represents an opportunity to
prevent or delay progression to dementia through modifications of risk factors such as depression and hypertension.
The identification of diagnostic tools to predict which patients may progress to more severe stages of the disease
has become a priority. The role of cognitive tests in the diagnosis of dementia is not questioned,because they show
the clinical decline in areas like speed of information processing, executive functions and reasoning (Sperling 2011
), while the role of biomarkers remains under evaluation (Kokkinou 2014; Ritchie 2014; Vacante 2013; Zhang 2014).
The Mini-Mental State Examination (MMSE) is a brief neuropsychological test that provides an overview of cognitive function
which, in the setting of patients with MCI, is supplemented with more specialized neuropsychological tests for other domains
of language, praxis and executive functions, among others. MMSE advantages reside in the easy way of administration
(especially in terms of time and resources) without direct harmful effects, as well as a high acceptability by the health
professionals involved in the management of people with dementia. In fact this popular test is frequently administered by
clinicians to MCI patients and our review could help them to interpret the results of MMSE of their patients. Ideally, this brief
cognitive test could be used for initial classification of MCI patients in order to determine their needs in a further and
comprehensive assessment. However, there might be occasions where an extensive and formal neuropsychological
evaluation is not available. In both cases it is important that clinicians know the limitations related to the use of this test in the
prediction of dementia for MCI patients.
Our review did not find evidence supporting a substantial role of MMSE as a stand-alone single-administration test in the
identification of MCI patients who may develop dementia. For example, a MCI patient with a baseline probability of 39% to
develop ADD in the next three to four years (median incidence of ADD in our studies) only increases his or her post-test
probability to 63% (95% CI 49 to 75) using a MMSE score indicator of progression (LR+ = 2.67), while a negative MMSE
score for progression only decreases his or her post-test probability to 27% (LR - = 0.58, 95% CI 20 to 34). In the case of
progression to dementia in general we found similar results. In all cases, clinicians would prefer to request additional and
extensive tests to be sure about the management of these patients. Also, the review has not been able to address some
critical issues such as an optimal cut-off, the influence of educational background, or even the effects of literacy in the
accuracy of MMSE.
We think that MMSE items, despite the fact that they cover several cognitive domains, are insufficient for registering subtle
cognition changes in MCI patients, especially for detecting those dementias without an important decline in the memory
domain (such as frontotemporal dementia and primary progressive apraxia). It is important that clinicians are aware of the
limitations related to the use of MMSE as a stand-alone single-administration test and seek to either use MMSE as a follow-
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up to detect changes in time, or to use it in the context of comprehensive assessments with more specialized
neuropsychological tests for other domains of language, praxis and executive functions.
Implications for research 
At present, the identification of useful cognitive tests that are able to detect subtle cognitive changes in people at different
stages of dementia has become an important challenge. Although the information included in this review does not support
the extended use of the MMSE in the stage of progression of MCI to dementia, we should not forget that this kind of test
could be useful in settings where formal neuropsychological assessment is not available. In order to determine, with more
information, the true operative characteristics of this test future research could focus on the evaluation of unique and pre-
specified diagnostic thresholds, as well as improving the appropriate reporting of variables such as education levels and
literacy. Likewise, it is essential to know if there are subsets of MMSE items which could be more strongly associated with
progression to dementia. If such a subset of items exists, clinicians will be confident that those results denote conversion to a
particular kind of dementia (for instance, conversion to ADD determined by the memory items of the MMSE).
An important aspect to consider in future updates is if conversion to dementia from MCI stages could be predicted better by
MMSE changes over time instead of isolated measurements. The role of repeated measurements of MMSE might be more
informative than baseline scores, but a formal evaluation of the utility of numerical differences between serial MMSEs has not
been performed yet. Finally, although the alternative of a single indicator for progression to dementia is attractive, it would be
more interesting to assess if a set of tests, rather than an isolated one, may be more successful in predicting conversion from
MCI to dementia. A diagnostic model composed of different cognitive and biomarker tools could be more useful for this
condition.
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Differences between protocol and review 
1. Target condition was amended to reflect the group of dementia in general (defined by studies): "The target condition was
conversion at follow-up from MCI to Alzheimer's disease dementia or other forms of dementia." change to "The target
condition was conversion at follow-up from MCI to all-cause dementia, Alzheimer's disease dementia or other forms of
dementia."
2. The objective was amended to reflect the group of dementia in general (defined by studies): "To determine the diagnostic
accuracy of the MMSE at various thresholds for detecting individuals with MCI at baseline who would clinically convert to
Alzheimer’s disease dementia or other forms of dementia at follow-up" changed to "To determine the diagnostic accuracy of
the MMSE at various thresholds for detecting individuals with MCI at baseline who would clinically convert to all-cause
dementia, Alzheimer’s disease dementia or other forms of dementia at follow-up"
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3. We planned (Arevalo-Rodriguez 2013a) to investigate the following but these investigations were not undertaken due to
the scarcity of data.
Index test
Thresholds
Technical features (including different versions of the test)
Operator characteristics (e.g. training)
Target disorder
Reference standards used: DSM definition, ICD definition, NINDS-ARDRA or other classification, including pathological
definitions, and operationalisation of these classifications (e.g. individual clinician, algorithm, consensus group)
Spectrum of target disorder
Target population
Age, sex, education, sociocultural variables (social network/social engagement)
Other characteristics (e.g. APOE status, definition and duration of MCI at baseline (if applicable))
Prevalence in different settings
Treatment: previous or current interventions
Study quality
Types of studies
Prior clinical information to increase the accuracy of the index test
Duration of follow-up (measured in years for delayed-verification studies)
Loss to follow-up
Published notes 
Characteristics of studies
Characteristics of included studies 
Buchhave 2008
Patient Selection
A. Risk of Bias
Patient Sampling
148 MCI patients who performed the cube
copying test were recruited from a memory clinic
in a prospective manner. Sampling procedure is
not fully described (mostly referred by general
practitioners). Exclusion criteria involves:
patients with other causes of cognitive
impairment, including brain tumour, subdural
haematoma, CNS infection, major depressive
episode, schizophrenia and current alcohol
abuse
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
This study included 148 MCI participants who
performed the cube copying test and were
diagnosed by the Petersen 1999 criteria at
baseline. Physicians specialised in cognitive
disorders performed a thorough physical,
neurological and psychiatric examination, as well
as a clinical interview, of each patient at baseline.
Furthermore, analysis of apolipoprotein E
(APOE) genotype and computed tomography of
the brain were done
Gender: 32 M, 30 F in MCI-stable group; 20 M,
43 F in MCI-AD group; 14 M, 8 F in MCI-other
dementias group
Age: 66.2±8.8 years in MCI-stable; 74.6±6.1
years in MCI-AD; 72.7±9.0 years in MCI-other
dementia
APOE ɛ 4 carrier: 32 in MCI-stable; 20 in MCI-
AD; 14 in MCI-other dementia
MMSE at baseline: MCI-stable 27.5±1.8; MCI-AD
26.8±1.4; MCI-other dementia 27.0 ± 1.7
Resources of referrals: "The majority of the
subjects with MCI (74.1%) were referred by their
general practitioners. The remaining MCI
subjects were referred by other physicians
(19.0%) or the patients themselves (6.8%)." Page
545
Resources of recruitment: memory disorder
clinic, Malmo University Hospital, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): no details about version, who administered and interpreted
the test and scoring systems are provided. No threshold is pre-specified. After analysis, authors
estimated threshold in 28/29 score
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Main target condition for conversion: conversion
from MCI to Alzheimer's disease dementia,
vascular dementia, dementia by Lewy bodies or
frontotemporal dementia
Reference standard: for ADD = NINCDS-ADRDA
+ DSM-IIIR criteria; for VaD = DSM-IIIR criteria +
NINDS-AIREN; for DLB = consensus criteria by
McKeith 1999; for frontotemporal dementia = Brun
1994
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of
the MMSE results? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: average 5.2 years (range 4 to 6.8 years)
At baseline :148 participants with MCI
At follow up: 147 participants: 63 MCI-AD; 22 MCI-other dementia (15 VD; 4 LBD; 1 SD; 1 FTD; 1
dementia induced by traumatic brain injury); 62 stable-MCI
Conversion to AD
N = 85; disease positive = 63; disease negative = 62 (p546); sensitivity = 89%; specificity = 33%
(Table 2, p548)
TP = 56; FP = 42; FN=7; TN=20 (Calculated in RevMan5)
Loss to follow-up: one participants died before 4 years follow-up (≅ 1%)
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Chopard 2009
Patient Selection
A. Risk of Bias
Patient Sampling
A cohort of 106/362 patients with QD (presence
of cognitive complaints+ no daily activities
affected + CDR = 0,5 + no DSM-IV criteria for
dementia) who attended local memory
impairment consultation centers and recruited
through the database of the Regional Network for
Diagnostic aids and Management of patients with
cognitive impairment in the Franche-Comtê
geographical area was included
Exclusion criteria: craniocerebral trauma, stroke
within 3 months from the beginning of the study,
acute neurological or somatic pathologies,
progressive psychiatric illness except major
depression
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
A cohort of 106 participants were followed-up
for 6 to 24 months (mean = 14.9 ± 4.5), from an
original sample of 362 patients with QD (59%
without follow-up)
Demographic data reported by total sample and
by conversion at follow-up (Tables 1 and 2):
Gender: 41.5% M, 58.5% F
Age: 75.7 ± 5.0 years
APOE 4 carrier: not reported
Education more than 12 years = 8.5%
MMSE at baseline: 25.2 ± 2.7
Sources of referral: the database of the
Regional Network for Diagnostic aids and
Management of patients with cognitive
impairment in the Franche-Comtê geographical
area
Sources of recruitment: the database of the
Regional Network for Diagnostic aids and
Management of patients with cognitive
impairment in the Franche-Comtê geographical
area
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): no details about version and scoring systems are provided. It
is unclear if threshold was pre-specified or not (26/27) and who administered and interpreted the test
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition:Conversion from MCI to Dementia and later
defined as ADD, VaD, DLB or FTD
Reference standard: dementia was defined according with
the following criteria: progressive worsening of cognitive
function at follow-up severe enough to affect IADLs and
progression of CDR score form 0.5 to 1. Standard criteria
were used for diagnosis of ADD (NINCDS-ADRDA), vascular
dementia (NINDS-AIREN), dementia for LB (McKeith criteria)
and frontotemporal dementia (Lund and Manchester criteria).
Dementia was defined independently of MMSE scores
Is the assessment used for clinical diagnosis of dementia
acceptable? Yes
Was clinical assessment for dementia performed without
knowledge of the MMSE results? Yes
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 6 to 24 months (mean 14.9 ± 4.5 months)
At baseline: 106 patients with QD
At follow-up: 38 converted to dementia; 68 remained free of dementia
TP = 29; FP = 41; FN = 9; TN = 27
Sensitivity: 76%; Specificity: 40% (calculated in RevMan5); cut-off: ≤ 26 (26/27) (page 705)
Loss to follow-up: none
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Conde-Sala 2012
Patient Selection
A. Risk of Bias
Patient Sampling
A longitudinal study (nested in a case-
control study) including 109 MCI patients
was analysed. In addition, no details about
recruitment of MCI patients were reported
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
A total of 109 participants with MCI, diagnosed
with the Portet criteria (2006), were recruited
from the Memory and Dementia Assessment
Unit.
Demographic data reported for total sample (N
= 342) (Page 950). There were no important
differences between the study groups in terms
of age, gender, marital status or schooling
Gender: 235 (69%) F; 107 (31%) M
Age: 74.3 ± 6.2 years
APOE 4 carrier: not reported
MMSE at baseline: 21.7 ± 3.3 MCI-converters;
21.0 ± 2.9 MCI-stable
Education: 21% illiterate or no formal schooling;
18% one to five, 50% six to eight and 11% more
than eight years of education respectively.
Sources of referral: not reported
Sources of recruitment: outpatient Memory and
Dementia Assessment Unit, Santa Catarina
Hospital, Girona, Spain
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): basic details provided. The test was administered by a team
of neuropsychologist from the hospital unit. No details about who interpreted the test. Used threshold
was pre-specified (21/22)
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Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standards: NINCDS-ADRDA
criteria for probable AD and DSM-IV-TR
criteria for AD
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of the
MMSE results? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 5 years
At baseline: 109 participants with MCI
At follow up: 43 MCI-AD converters; 66 MCI stable (non-converters)
Number included in analyses: 109
Conversion to AD
Information provided from the author (unpublished):
TP = 19; FP = 36; FN = 24; TN = 30
Sensitivity: 44.19%; Specificity: 45.45% (calculated in RevMan5); cut-off: ≤ 21 (21/22) (p949)
Loss to follow-up: none
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators was contacted; they provided requested data tor the 2 X 2 table
to be completed; e-mail from Dr Conde-Sala on 20 February 2014
 
Devanand 2008
Patient Selection
A. Risk of Bias
Patient Sampling
A total of 148 outpatients with memory
complaints (MCI broadly defined) from a
Memory Disorders Clinic were consecutive
recruited
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
A total of 148 patients were included in analysis.
Sample size estimation = 150 patients; two
patients were excluded by misdiagnosis.
Baseline MCI was determined post hoc due to
the study began before MCI criteria were
published
Demographic data presented for 39 MCi-
converters and 109 MCI non-converters was
provided on Table 1 (Page 14):
Gender: Converters: 56.4% F; Non-converters:
55.1% F
Age: Converters: 73.2± 7.1 years; Non-
converters: 64.9 ± 9.9 years
Education (years): Converters: 14 ± 4.7 years;
Non-converters: 15.4 ± 4.1 years
APOE ɛ4 carrier: Converters: 34.3%; Non-
converters: 23.6%
MMSE at baseline: Converters: 26.3± 2.2; Non-
converters: 27.9 ± 2.0
Sources of referral: the majority (52%) were
physician referred, 25% were self-referred, and
23% were referred by family or friends or other
sources (Devanand 2007)
Sources of recruitment: Memory Disorders Clinic
(jointly run by NY Psychiatric Institute, Columbia
University)
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): no details about version and scoring systems are provided. It
is unclear who administered the baseline test. Two expert raters reviewed the neuropsychological
information to determine inclusion
No threshold was used. Quote: "Based on the fitted logistic regression and dichotomizing estimated
risk at 0.5, likelihood ratios with 95% CI were calculated"
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Conversion from MCI to
Alzheimer`s disease dementia
Reference standard: DSM- IV criteria +
NINCDS-ADRDA criteria. The endpoint of
conversion to AD required diagnosis at two
consecutive annual outcome criteria
Two expert raters (DPD and YS) made a
consensus diagnosis at each follow-up,
while remaining blind to data from previous
visits (page 3)
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of the
MMSE results? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
At baseline = 148 patients were included
During 1 to 9 years of follow-up: 39 converters, 109 non-converters, 63 healthy controls
For analysis of sensitivity and specificity, authors selected a sub-sample of 125 patients with 3-years
of follow-up:
At 3-years of follow-up: 33 converters, 92 non-converters
TP = 9; FN = 9; FP = 24; TN = 83
Sensitivity = 26.8%; Specificity = 90% (calculated in RevMan5)
Loss to follow up: 22 patients dropped out before the 3-year follow up time-point
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Meguro 2007a
Patient Selection
A. Risk of Bias
Patient Sampling
This reference have two incidence studies
(called Meguro 2007a and Meguro 2007b
for this review). In the 2003 study (Meguro
2007a) 54 participants with CDR = 0.5 with
MRI results were analysed. Whole sample
included participants with CDR = 0 (204
patients)
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
A total of 54 participants with MCI ('questionable
dementia') diagnosed with CDR = 0.5 (Morris
1993) were included in study 2003. Those
participants were recruited from the same
community based population. Demographic data
presented for the MCI-converters (n = 133; Table
1, p178) was provided for both studies (Meguro
2007a and Meguro 2007b):
Gender: 45 M; 88 F
Age: 9 aged 65 to 69 years; 77 aged 70 to 79
years; 47 aged 80+
Sources of recruitment: community of Tajiri,
Japan
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
Mini-Mental state Examination (MMSE): Folstein version (1975, reference 25). A team of trained
psychologist performed MMSE blindly to the diagnosis and CDR
Threshold: “Abnormal MMSE data are assessed with reference to the participants’ educational levels
based on the old Japanese education system: 17/18 for 6 (or less) years of schooling, 20/21 for 8
years of schooling, and 23/24 for 10 (or more) years of schooling” (information provided from the
author)
Cut off: ˂ 17 or ˂ 20 or ˂ 23
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia, VaD, DLB or FTD
Reference standard: NINCDS-ADRDA for
probable AD; NINDS-AIREN for possible AD with
CVD; NINDS-AIREN for probable VaD; the
consensus guidelines for diagnosis of dementia
with Lewy bodies (DLB) (McKeith 2005), and the
Lund and Manchester Groups criteria for
frontotemporal dementia (McKhann 2001). A
clinical team comprising medical doctors and
public health nurses determined the follow-up
CDR blindly to the previous CDR stages, baseline
cognitive test scores, and MRI data
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of
the MMSE results? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Participants 2003 at baseline: N = 54
Duration of follow-up: 5 years
At follow-up: 20 MCI-dementia: 7 with abnormal MMSE (at baseline); 34 MCI-stable: 2 with abnormal
MMSE (at baseline) (information from the author)
TP=7; FN=13; FP=2; TN=32
Sensitivity=35%; Specificity=94% (Calculated in RevMan5)
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators were contacted; they provided requested data tor the 2 X 2 table
to be completed; e-mail from Dr Meguro on 4 March 2014
 
Meguro 2007b
Patient Selection
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A. Risk of Bias
Patient Sampling
This reference have two incidence
studies (called Meguro 2007a and
Meguro 2007b for this review). In the
2005 study (Meguro 2007b), 281 patients
without MRI results were analysed
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
A total of 281 participants with MCI
('questionable dementia') diagnosed with CDR =
0.5 (Morris 1993) were included in 2005 study.
Those participants were recruited from the same
community based population. Demographic data
presented for the MCI-converters (n=133; Table
1, p178) was provided for both studies (Meguro
2007a and Meguro 2007b):
Gender: 45 M; 88 F
Age: 9 aged 65 to 69 years; 77 aged 70 to 79
years; 47 aged 80+
Sources of recruitment: community of Tajiri,
Japan
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): Folstein version (1975, reference 25). A team of trained
psychologist performed MMSE blindly to the diagnosis and CDR
Threshold: “Abnormal MMSE data are assessed with reference to the participants’ educational levels
based on the old Japanese education system: 17/18 for 6 (or less) years of schooling, 20/21 for 8
years of schooling, and 23/24 for 10 (or more) years of schooling” (information provided from the
author)
Cut off: ˂ 17 or ˂ 20 or ˂ 23
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
dementia
Reference standard: DSM-IV and CDR 1
+. A clinical team comprising medical
doctors and public health nurses
determined the follow-up CDR blindly to
the previous CDR stages, baseline
cognitive test scores, and MRI data
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of the
MMSE results? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Participants 2005 (at baseline): N = 281
Duration of follow-up: 7 years
At follow-up: 113 MCI-dementia: 26 with abnormal MMSE (at baseline); 168 MCI-stable: 14 with
abnormal MMSE (at baseline) (information from the author)
TP = 26; FN = 87; FP = 14; TN = 154
Sensitivity = 23%; Specificity = 92% (calculated in RevMan5)
Loss to follow-up: none
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators were contacted; they provided requested data tor the 2 X 2 table
to be completed; e-mail from Dr Meguro on 4 March 2014
 
Modrego 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Cohort of 59 consecutive amnestic MCI
patients referred from the community by
family physicians for recent memory
complaints
Exclusion criteria: not detailed
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
A total of 59 consecutive patients with memory
complaints and criteria for MCI were recruited
from a outpatient clinic. The authors asked the
general practitioners to refer to them all elderly
patients with memory complaints and then they
included all who fulfilled the criteria for
amnestic mild cognitive impairment (Petersen
1999). The final diagnosis was made by taking
into account as much information as possible
from all sources.
Baseline demographic data are reported inside
the text (Page 670) and in the table 1:
Gender: 34 F, 21 M
Age: 72.7 years ± 5.3
APOE 4 carrier: Not reported.
MMSE at baseline: 27.6 ± 3.6
Sources of referral: primary practitioners
Sources of recruitment: Outpatient clinic at
Spain
Are there concerns that the included patients and setting do not match the
review question? Unclear
Index Test
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Index tests
Mini-Mental state Examination (MMSE): Spanish version which has a maximum of 35 points and a cut-
off point of 23 for elderly subjects. No details about who administered and interpreted the test. Used
threshold was not pre-specified (at 1 year, 26 points or less; at 3 years, 29 points or less)
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Main target condition: conversion from MCI
to dementia and ADD (unclear information)
Reference standard: NINCDS-ADRDA
criteria
Is the assessment used for clinical diagnosis of dementia acceptable? Unclear
Was clinical assessment for dementia performed without knowledge of the
MMSE results? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 1 year and 3 years
In 1 year: 
Patients at baseline: 53/55 patients; one patient was lost and another non-demented patient had died
from cardio-embolic stroke
13 patients (53%) converted to AD
MMSE cut-off ≤ 26: TP = 8; FP = 7; FN = 5; TN = 33 (calculated in Revman5)
In 3 years:
Patients at baseline: 53/53 patients; no losses to follow-up
29 patients (55%) converted to AD
MMSE cut-off ≤ 29: TP = 22; FP = 8; FN = 7; TN = 16 (calculated in Revman5)
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Unclear
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Unclearrisk
Notes
Notes  
Modrego 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Cohort of 105 patients with subjective memory
complaints and referred by family physicians were
assessed between December 2007 to April 2011 in
an outpatient clinic of a university hospital in
Zaragoza, Spain
Exclusion criteria: patients with hydrocephalus,
chronic psychiatric conditions, large infarcts of the
brain or those who met the NINCDS-ADRDA
criteria for dementia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
A total of 105 patients with subjective memory
complaints corroborated by an informant
(relative or caregiver), preservation of daily
living activities, no behavioral symptoms (BDRS
< 4), and normality in global cognitive function
(MEC > 23 or > 26 by age; CDR 0,5) were
included
Demographic data reported for 105 participants
(Table 1, p7)
Age: converters 76 ± 9 years; non-converters:
72.4 ± 6.6 years
APOE4 carrier: not provided
MMSE: converters 27.6 ± 2.7; non-converters
29.8 ± 2.8
Education: University: converters = 3.5%; non-
converters = 8.3%
Sources of referral: family physicians
Sources of recruitment: unclear
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): Spanish version which has a maximum of 35 points. No
details about who administered and interpreted the test at baseline. Used threshold was no pre-
specified
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Main target condition: conversion from
MCI to probable AD
Reference standard: NINCDS-ADRDA
criteria
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of the
MMSE results? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: median of 2 years (range 1 to 4 years)
Patients at baseline: 105/110 patients; 5 patients were excluded at baseline according with exclusion
criteria
57 patients (54.2%) converted to AD
MMSE cut-off ≤ 30/35: TP = 26; FP = 6; FN = 31; TN = 42 (calculated in Revman5)
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Palmqvist 2012
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Patient Selection
A. Risk of Bias
Patient Sampling
A MCI cohort of 133 MCI patients referred to the
clinic between 2000 to 2006 were assessed. Most
patients were referred from primary care units, but
some referrals came from other clinics at the
hospital. No further details about recruitment were
reported
Exclusion criteria: patients with diagnosis of
haematoma, brain tumour, CNS infection,
schizophrenia, major depressive episode or
current alcohol abuse were not included
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
A total of 133 participants with MCI, diagnosed
with the Petersen 2004 criteria, were recruited
in the memory clinic. Baseline demographic
data reported in table 1 (p4)
Gender: MCI-MCI: 34 F, 28 M; MCI-AD: 36 F,
16 M; MCI-other dementias: 8 F, 11 M
Age: MCI-MCI: 69.8 years (55 to 85); MCI-AD:
75.3 years (55 to 87); MCI-other dementias:
71.2 years (59 to 83)
APOE4 carrier: MCI-MCI: 28; MCI-AD: 39;
MCI-other dementias: 12
MMSE: MCI-MCI: mean 28.1 ± 1.2; MCI-AD:
mean 26.1 ± 1.5; MCI-other dementias: mean
27.1 ± 2.0
MMSE (O & R): MCI-MCI: mean 11.4 ± 1.1;
MCI-AD: mean 9.6 ± 1.4; MCI-other
dementias: mean 10.9 ± 1.3
Education: not reported
Sources of referral: most patients were
referred from primary care units, but some
referrals came from other clinics at the hospital
Sources of recruitment: memory clinic of
Skane University Hospital, Malmö, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): Full details provided. The test was administered by physicians
experienced in dementia disorders. also, the items about orientation and recall (MMSE O&R) are
assessed. Used thresholds were not pre-specified
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia, vascular
dementia, dementia with Lewy bodies
Reference standard: AD:NINCDS-ADRDA
criteria, Vascular dementia (VaD); either
probable VaD according to NINDS-AIREN
(Roman 1993) or subcortical VaD according to
Erkinjuntti 2000, Dementia with Lewy bodies
(DLB): according to the McKeith 2005 criteria
A consensus group of three study physicians
experienced in dementia disorders (OH, JH
and LM) later determined all diagnoses. The
physicians were blinded to the CSF and
cognitive test data collected on the initial visit
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of the
MMSE results? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean 5.9 years (range 3.2 to 8.8 years)
At baseline: 133 MCI
At follow up: 71 MCI converters (52 MCI-AD; 10 MCI-VD; 4 MCI-DLB; 3 MCI-PSP; 1 MCI-SD; 1 MCI-
dementia due to brain tumour); 62 MCI stable
Table 2: ROC curve analysis: predicting follow-up AD diagnosis
1) MMSE (cut-off ˂ 27): sensitivity = 62%; specificity = 84%
Conversion to AD dementia: N = 133: 52 AD (‘disease positive’) and 81 ‘disease negative’ (non-AD)
TP = 32; FP = 13; FN = 20; TN = 68 (calculated in Revman5)
2) MMSE (O & R) (cut-off ˂ 10): sensitivity = 54%; specificity = 94%
Conversion to AD dementia: N = 133: 52 AD (‘disease positive’) and 81 ‘disease negative’ (non-AD)
TP = 28; FP = 5; FN = 24; TN = 78 (calculated in RevMan 5)
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators contacted; they confirmed that there was no overlapping
between samples in two papers, Palmquist 2012 and Buchhave 2008. E-mail from Dr
Palmqvist on 28 February 2014
 
Pozueta 2011
Patient Selection
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A. Risk of Bias
Patient Sampling
Consecutive sample of 115 MCI participants was
recruited from a memory clinic between 2007 and
2008
Exclusion criteria: participants who met criteria for
dementia (DSM-IV), AD (NINCDS-ADRDA),
depressive episode (IDC-10), subjects with
significant cerebrovascular disease (Hachinski scale
score 0.4), and those with any other medical or
psychiatric identifiable cause accounting for their
complaints
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
A total of 115 participants with MCI, diagnosed
initially with the Petersen 2004 criteria were
recruited from a memory clinic
Demographic data reported for 105 participants
(Table 1, p3)
Gender: total: 65 F, 40 M; converters: 30 F, 20
M; non-converters: 35 F, 20 M
Age: converters 75.94 ± 6.05 years; non-
converters: 72.93 ± 7.3 years
APOE4 carrier: converters 27; non-converters
16
MMSE: converters 25.92 ± 1.88; non-converters
27.78 ± 1.55
Education: not reported
Sources of referral: not reported
Sources of recruitment: memory clinic of the
University Hospital
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): no details about version, who administered and interpreted
the test and scoring systems are provided. Used threshold was not pre-specified
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standards for identifying the
target conditions at follow-up were not
reported
Is the assessment used for clinical diagnosis of dementia acceptable? Unclear
Was clinical assessment for dementia performed without knowledge of the
MMSE results? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 2 years
At follow-up: 50 AD dementia; 2 LBD; 2 VaD, 55 MCI-S (MCI stable, non-converters)
Number included in analyses: 105 (excluding 2 patients with LBD; 2 with VD)
Number included in analyses: 105
Conversion to AD
Sensitivity: 64%; Specificity: 80%; cut-off: ≤ 26 (Table 2, p3) (disease positive = 59; disease negative =
292)
TP = 32; FP = 11; FN = 44; TN = 18 (calculated in RevMan5)
Loss to follow-up: 6 participants did not complete the first year of follow-up, so they were not included
in analyses
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Unclear
Were all participants included in the final analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Xu 2002
Patient Selection
A. Risk of Bias
Patient Sampling
Retrospective cohort of 351 consecutive patients
attending outpatient research clinic, admitted
between 1992 and 1997 and referred by
specialists, primary care physicians or self-
referred
Exclusion criteria: subjects with pre-existing
dementia, non-dementing organic brain
disorders, epilepsy, previous strokes and
infectious central nerve system diseases
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
351 participants with subjective memory
complaints
Gender:140 M; 211 F
Age: mean age 67 years (SD 11.23)
APOE4 carrier: not provided
Resources of referral: specialists and
primary care physicians; in addition, many
relatives, friends and caregivers volunteered
to participate (self-referrals)
Resources of recruitment: outpatient
research clinic, Houston and Southwest
United States
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
Mini-Mental state Examination (MMSE): full details about version. Unclear who administered and
interpreted the test. Used threshold was not pre-specified
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from SMC to
Alzheimer's disease dementia, vascular dementia,
dementia by Lewy bodies or frontotemporal
dementia
Reference standard: for AD = NINCDS-ADRDA;
VaD = NINDS-AIREN; DLB = McKeith criteria;
FTD = Lund and Manchester criteria
Is the assessment used for clinical diagnosis of dementia acceptable? Yes
Was clinical assessment for dementia performed without knowledge of
the MMSE results? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 3 to 6 years (mean 3.89 ± 2.17 years)
Number included in analyses: 351
1) Conversion to probable AD: N = 47 probable AD and 304 non-AD (37 non-AD dementias and 267
MCI stable); disease positive = 47; disease negative = 304
Sensitivity: 61%; Specificity: 82.9%; cut-off: ≤ 26 (27/26 scores) (Table 2, p1030)
TP = 29; FP = 52; FN = 18; TN = 252 (calculated in RevMan5)
2) Conversion to probable VaD: N = 22 probable VaD and 329 non-VaD (62 non-VaD dementias and
267 MCI stable): disease positive = 22; disease negative = 329
Sensitivity: 36.4%; Specificity: 80%; cut-off: ≤ 25 (26/25 scores) (Table 3, p1030)
TP = 8; FP = 65; FN = 14; TN = 264 (calculated in RevMan5)
3) Conversion to all dementias: N = 84 all dementia and 267 non-converters (267 MCI stable): disease
positive = 84; disease negative = 267
Sensitivity: 57.1%; Specificity: 85.8%; cut-off: ≤ 26 (27/26 scores) (Table 4, p1030)
TP = 48; FP = 38; FN = 36; TN = 229 (calculated in RevMan5)
Loss to follow-up: all participants who completed at least three years of longitudinal cognitive
assessment were included in the analysis
Was there an appropriate interval between MMSE and the reference standard? Yes
Did all participants receive the same reference standard? Yes
Were all participants included in the final analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Footnotes
Characteristics of excluded studies 
Aevarsson 2000
Reason for exclusion Change in MMSE scores from general population (no MCI patients) to dementia are
detailed (logistic regression results)
 
Apostolova 2006
Reason for exclusion MMSE is assessed as a predictor of conversion to dementia for MCI patients (logistic
regression results), but the authors do not provide information about the accuracy of
any threshold
 
Armas 2009
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Reason for exclusion Descriptive information about MMSE is provided without data about its accuracy
 
Brodaty 2011
Reason for exclusion Study focused on cognitive decline (based on MMSE); no accuracy information is
provided
 
Bruck 2013
Reason for exclusion Descriptive information about MMSE is provided without data about its accuracy
 
Chan 2011
Reason for exclusion Baseline MMSE is assessed as a predictor of conversion to dementia for MCI patients
(logistic regression results), but the authors do not provide information about the
accuracy of any threshold
 
Chilovi 2011
Reason for exclusion Descriptive information about MMSE is provided without data about its accuracy
 
Choi 2013
Reason for exclusion Descriptive information about MMSE is provided without data about its accuracy
 
Cruz 2012
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Devanand 2010
Reason for exclusion Baseline MMSE scores are evaluated as a part of a model; individual accuracy data
are not provided
 
Devier 2009
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Devier 2010
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Ehrensperger 2010
Reason for exclusion MMSE is not evaluated as a factor of conversion (no follow-up)
 
Ewers 2007
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Hampel 2004
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Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Ito 2013
Reason for exclusion MMSE is included in a logistic regression model; no data about accuracy are provided
 
Koepsell 2012
Reason for exclusion MMSE is included in a logistic regression model; no data about accuracy are provided
 
Korf 2004
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Kruczyk 2012
Reason for exclusion MMSE is included in a rule-based model; no data about accuracy are provided
 
Li 2011
Reason for exclusion We made request to authors to obtain useable data, but we did not receive response.
At the time to publish this review, we did not had enough information to include this
study
 
Luck 2012
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Madureira 2010
Reason for exclusion MMSE is included in a logistic regression model
 
Mauri 2012
Reason for exclusion We made request to authors to obtain useable data, but we did not receive response.
At the time to publish this review, we did not had enough information to include this
study
 
Meyer 2002
Reason for exclusion MMSE is not evaluated as a factor of conversion
 
Ott 2013
Reason for exclusion Descriptive information about MMSE is provided without data about its accuracy
 
Ouchi 2012
Reason for exclusion MMSE is included in a logistic regression model; no data about accuracy are provided
 
Paajanen 2014
Reason for exclusion MMSE is not evaluated as a factor of conversion
 
Rosenberg 2013
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Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Serrano 2007
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Tardif 2013
Reason for exclusion MMSE is not evaluated as a factor of conversion
 
Van Rossum 2011
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
van Rossum 2012
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Waldorff 2012
Reason for exclusion MMSE is included in a Cox proportional hazard model; no data about accuracy are
provided
 
Wong 2013
Reason for exclusion Participants not individuals with MCI at baseline. MMSE is not evaluated as a factor of
conversion
 
Zhang 2012
Reason for exclusion MMSE is included in a sparse linear regression model; no data about accuracy are
provided
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Hall 2012
Study name Utility of NPI Scores predicting progression of CIND to dementia
 
Target condition and reference
standard(s)
Target condition: dementia
Reference standard: unclear
 
Index and comparator tests Neuropsychiatric Inventory (NPI)
 
Starting date Not provided
 
Contact information J Hall; Bl Plassman; D Steffens
 
Notes Information from a conference abstract
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Footnotes
Summary of results tables
1 Summary of findings table
What is the diagnostic accuracy of MMSE scores at baseline for identifying those MCI participants who would convert to
dementia, Alzheimer´s disease dementia or other forms of dementia over time?
Patient
population
Participants diagnosed with MCI at baseline using Petersen and revised Petersen criteria (Petersen 1999;
Petersen 2004), Matthews criteria (Matthews 2008) or Clinical Dementia Rating (CDR) = 0.5 (Morris 1993)
Prior testing Most tests are usually performed after a cognitive deficit has been identified
Settings Participants were recruited from: i) secondary care - outpatient clinic (n = 3); ii) secondary care – memoryclinics (n = 6) and iii) populational sources (n = 2)
Index tests MMSE scores at baseline
Reference
standard
NINCDS-ADRDA or DSM or ICD criteria for Alzheimer’s disease dementia; McKeith criteria for Lewy body
dementia; Lund criteria for frontotemporal dementia; and NINDS-AIREN criteria for vascular dementia
Target
condition Dementia in general (defined by studies), Alzheimer’s disease dementia or other forms of dementia
Included
studies 11 studies (1569 participants) of prospectively cohorts with any accepted definition of MCI were included
Quality
concerns
Patient selection and index test domains were insufficiently reported. Seven studies have not pre-specified
thresholds
Regarding the reference standard domain, a significant number of studies did not have enough information
about the independent interpretation between the MMSE scores and the final diagnosis
There were not important concerns about applicability domains in general
Limitations Limited investigation of heterogeneity due to insufficient number of studies
Test Studies Cases/participants
Median
specificity from
included studies
Sensitivity at
median
specificity (1)
Consequences in a cohort of 100
Median
percentage
converting (range)
(2)
Missed
cases (3) Overdiagnosed
All-cause dementia
MMSE scores
at baseline 4 255/792 88% 40% 36.5 (23.9 to 40.2) 22 8
Alzheimer’s disease dementia
MMSE scores
at baseline 8 374/1128 80% 54% 39.1 (13.3 to 47.6) 18 12
Non-Alzheimer’s disease dementia (vascular dementia)
MMSE scores
at baseline 1 22/351 80% 36% 6.26 5 19
Investigation
of
heterogeneity
The planned investigations were not possible due to the limited number of studies available for each
analysis
Conclusions
Our review did not find the evidence for supporting a substantial role of MMSE test in identifying those MCI
patients who would develop dementia. The information included in this review is heterogeneous and does
not present a definitive answer about critical issues such as an optimal cut-off, the influence of educational
background or even the effects of literacy in the accuracy of MMSE
(1) Meta-analytic estimate of sensitivity derived from the HSROC model at the median value of specificity computed from
the included studies. Summary estimates of sensitivity and specificity were not computed due to high heterogeneity derived
from included studies.
(2) The median percentage of conversion and range were computed using all the studies included in the analysis for each
target condition.
(3) Missed (false negative) and overdiagnosed (false positive) numbers were computed using the median percentage of
conversion for each target condition.
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Footnotes
2 Table of descriptive data
ID Countryof Study Setting
Years of
education
Language(s)
of tests
MMSE
Diagnostic
Threshold
Target
condition
Definition of
dementia
Follow-
up Definition MCI
Buchhave
2008
Sweden Memory
clinic
Not provided Unclear 28/29 ADD DSM III-R +
NINCDS-ADRDA
5,2
years
(4 to
6.8)
Petersen
criteria
Conde-
Sala 2012
Spain Memory
clinic
50% had
attended
school for six
to eight years
Spanish 21/22 ADD DSM-IV-TR or
NINCDS-ADRDA
5 years European AD
consortium
(EADC) criteria
for MCI
Chopard
2009
France Memory
clinic
≥ 12 years of
education =
8.5%
Unclear 26/27 All-cause
dementia
IADLs scores
affected + CDR =
0.5 to 1 and
DSM-IV + CDR =
1 + plus NINCDS-
ADRDA or
NINDS-AIREN or
criteria for DLB or
Lund and
Manchester
criteria
14.9
months
(± 4.5)
Presence of
cognitive
complaints +
no daily
activities
affected +
CDR = 0.5 +
no DSM-IV
criteria for
dementia
Devanand
2008
USA Memory
clinic
Converters =
14 (4.7)
Non-
converters=
15.4 (4.1)
English Not
provided
ADD DSM-IV +
NINCDS-ADRDA
3 years Petersen
criteria
Meguro
2007a
Japan Population
sample
8.3 years Japanese 17/18 for 6
or less
years of
education
20/21 for 7
to 8 years
23/24 for
10 or more
years
All-cause
dementia
DSM-IV + CDR =
1 + plus NINCDS-
ADRDA or
NINDS-AIREN or
criteria for DLB or
Lund and
Manchester
criteria
5 years CDR = 0.5
Meguro
2007b
Japan Population
sample
No provided Japanese 17/18 for 6
or less
years of
education
20/21 for 7
to 8 years
23/24 for
10 or more
years
All-cause
dementia
DSM-IV + CDR =
1
7 years CDR = 0.5
Modrego
2005
Spain Outpatient
clinic
No provided Spanish 26/27 from
35; 29/30
from 35
ADD NINCDS-ADRDA 1 to 5
years
Petersen
criteria for
amnestic MCI
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ID Countryof Study Setting
Years of
education
Language(s)
of tests
MMSE
Diagnostic
Threshold
Target
condition
Definition of
dementia
Follow-
up Definition MCI
Modrego
2013 Spain
Outpatient
clinic
Converters =
elementary:
78.9%; high
school:
17.5%;
university:
3.5%
Non-
converters =
elementary:
79.2%; high
school:
12.5%;
university:
8.3%
Spanish 30/31 from35 ADD NINCDS-ADRDA
2 years
(1 to 4)
CDR = 0.5 +
BDRS < 4
Palmqvist
2012
Sweden Memory
clinic
No provided Swedish 26/27; 9/10
for O&R
subscale
ADD NINCDS-ADRDA 5.9
years
(3.2 to
8.8)
Petersen
criteria
Pozueta
2011
Spain Memory
clinic
% primary
school:
Pr-AD = 66.6
S-MCI =
71.42
Spanish 26/27 ADD Unclear 2 years Petersen
criteria
Xu 2002
USA
Outpatient
research
clinic
Non-dementia
= 12.17 (5.23)
All dementias
= 10.06 (6.11) English
26/27 for
dementia or
AD; 25/26
for VaD
All-cause
dementia,
ADD
VaD
NINCDS-ADRDA
or NINDS-AIREN
or criteria for
dementia by Lewy
bodies or Lund
and Manchester
criteria or NINDS-
SPSP
3.89 (2
to 17) Unclear
Footnotes
See 'Characteristics of included studies' for more detailed study descriptors.
Abbreviations: ADD = Alzheimer´s Disease Dementia; CDR = Clinical Dementia Rating; DSM = Diagnostic and Statistical
Manual of Mental Disorders; ICD-10 = International Statistical Classification of Diseases and Related Health Problems 10th
Revision; MCI = Mild cognitive Impairment; MMSE = Mini-Mental State Examination; NINCDS-ADRDA = National Institute of
Neurological and Communicative Disorders and Stroke and the Alzheimer´s Disease and Related Disorders Association;
NINDS-AIREN = National Institute of Neurological Disorders and Stroke and Association Internationales pour la Recherche
et l´Ensignement en Neurosciences; O&R = MMSE´s Orientation and Recall items; Pr-AD = Prodormal AD; USA = United
States of America; VaD = Vascular Dementia.
3 Sensitivity and specificity distribution by cut-off
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Cut-off Buchhave2008
Conde-
Sala 2012
Chopard
2009
Devanand
2008
Meguro
2007a
Meguro
2007b
Modrego
2005
Modrego
2013
Palmqvist
2012
Pozueta
2011 Xu 2002
All-cause dementia
26/27     0.76/0.40               0.57/0.86
By
education
level
        0.35/0.94 0.23/0.92          
ADD
21/22   0.44/0.45                  
26/27                 0.62/0.84 0.64/0.80 0.62/0.83
28/29 0.89/0.33                    
29/30
(max 35
points)
            0.76/0.67        
30/31
(max 35
points)
              0.45/0.87      
No
provided
      0.27/0.90              
VaD
26/27                     0.36/0.80
Footnotes
Abbreviations: ADD = Alzheimer´s Disease Dementia; VaD = Vascular Dementia.
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Study flow diagram.
Figure 2
Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies.
Figure 3
Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study.
Figure 4 (Analysis 1) 
Caption
Forest plot of 1 MMSE conversion to all-cause dementia.
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Caption
Baseline MMSE scores - conversion from MCI to all-cause dementia.
Figure 6 (Analysis 2) 
Caption
Forest plot of 2 MMSE conversion to ADD.
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MMSE scores conversion from MCI to ADD.
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Appendices 
1 Search strategies
 
Source
Search strategy
 
1. MEDLINE In-process and other non-
indexed citations and MEDLINE 1946-
present (OvidSP) up to May 2014
1. MMSE*.ti,ab.
2. sMMSE.ti,ab.
3. Folstein*.ti,ab.
4. MiniMental.ti,ab.
5. "mini mental stat*".ti,ab.
6. or/1-5
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2. EMBASE
1980-2014 May 16 (OvidSP)
 
1. MMSE*.ti,ab.
2. sMMSE.ti,ab.
3. Folstein*.ti,ab.
4. MiniMental.ti,ab.
5. "mini mental stat*".ti,ab.
6. 3MS.ti,ab.
7. *mini mental state examination/
8. or/1-7
9. dement*.ti,ab.
10. alzheimer*.ti,ab.
11. exp *dementia/
12. "vascular cognitive impair*".ti,ab.
13. ("lewy bod*" or DLB or LBD).ti,ab.
14. (AD or VaD or FTLD or FTD or DLB or LDB).ti,ab.
15. delirium/
16. deliri*.ti,ab.
17. or/9-16
18. exp *mild cognitive impairment/
19. "cognit* impair*".ti,ab.
20. (forgetful* or confused or confusion).ti,ab.
21. MCI.ti,ab.
22. ACMI.ti,ab.
23. ARCD.ti,ab.
24. SMC.ti,ab.
25. CIND.ti,ab.
26. BSF.ti,ab.
27. AAMI.ti,ab.
28. LCD.ti,ab.
29. QD.ti,ab.
30. AACD.ti,ab.
31. MNCD.ti,ab.
32. MCD.ti,ab.
33. (nMCI or aMCI or mMCI).ti,ab.
34. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
35. "Petersen criteria".ab.
36. ((CDR adj2 "0.5") or ("clinical dementia rating" adj3 "0.5")).ab.
37. "cognit* declin*".ti,ab.
38. "cognit* deficit*".ti,ab.
39. or/18-38
40. 17 or 39
41. 8 and 40
 
3. PSYCINFO
1806-May week 3 2014 (OvidSP)
 
1. exp Dementia/
2. exp Delirium/
3. exp Huntingtons Disease/
4. exp Kluver Bucy Syndrome/
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5. exp Wernickes Syndrome/
6. exp Cognitive Impairment/
7. dement*.mp.
8. alzheimer*.mp.
9. (lewy* adj2 bod*).mp.
10. deliri*.mp.
11. (chronic adj2 cerebrovascular).mp.
12. ("organic brain disease" or "organic brain syndrome").mp.
13. "supranuclear palsy".mp.
14. ("normal pressure hydrocephalus" and "shunt*").mp.
15. "benign senescent forgetfulness".mp.
16. (cerebr* adj2 deteriorat*).mp.
17. (cerebral* adj2 insufficient*).mp.
18. (pick* adj2 disease).mp.
19. (creutzfeldt or jcd or cjd).mp.
20. huntington*.mp.
21. binswanger*.mp.
22. korsako*.mp.
23. ("parkinson* disease dementia" or PDD or "parkinson* dementia").mp.
24. or/1-23
25. "cognit* impair*".mp.
26. exp Cognitive Impairment/
27. MCI.ti,ab.
28. ACMI.ti,ab.
29. ARCD.ti,ab.
30. SMC.ti,ab.
31. CIND.ti,ab.
32. BSF.ti,ab.
33. AAMI.ti,ab.
34. MD.ti,ab.
35. LCD.ti,ab.
36. QD.ti,ab.
37. AACD.ti,ab.
38. MNCD.ti,ab.
39. MCD.ti,ab.
40. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
41. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
42. "preclinical AD".mp.
43. "pre-clinical AD".mp.
44. ("preclinical alzheimer*" or "pre-clinical alzheimer*").mp.
45. (aMCI or MCIa).ti,ab.
46. ("CDR 0.5" or "clinical dementia rating scale 0.5").ti,ab.
47. ("GDS 3" or "stage 3 GDS").ti,ab.
48. ("global deterioration scale" and "stage 3").mp.
49. "Benign senescent forgetfulness".ti,ab.
50. "mild neurocognit* disorder*".ti,ab.
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51. (prodrom* adj2 dement*).ti,ab.
52. "age-related symptom*".mp.
53. (episodic adj2 memory).mp.
54. ("pre-clinical dementia" or "preclinical dementia").mp.
55. or/25-54
56. 24 or 55
57. mini mental state examination/
58. "mini mental stat*".ti,ab.
59. MiniMental.ti,ab.
60. Folstein*.ti,ab.
61. sMMSE.ti,ab.
62. MMSE*.ti,ab.
63. or/57-62
64. 56 and 63
 
4. Biosis previews 1926 to present (ISI
Web of Science) to 20 May 2014
 
Topic=(MMSE OR sMMSE OR "mini mental stat*" OR folstein* OR MiniMental)
AND Year Published=(1975-2012) AND Topic=(detect* OR diagnos* OR predict*
OR identify OR validity OR validation OR validate OR utility OR sensitivity OR
specificity OR screen* OR preval* OR incidence) AND Topic=(dement* OR
alzheimer* OR cognitive OR cognition OR memory OR MCI OR petersen)
Databases=BIOSIS Previews.
Lemmatization=On
 
5. Web of Science and conference
proceedings (1945-present) to 20 May
2014
 
Topic=(MMSE OR sMMSE OR "mini mental stat*" OR folstein* OR MiniMental)
AND Year Published=(1975-2012) AND Topic=(detect* OR diagnos* OR predict*
OR identify OR validity OR validation OR validate OR utility OR sensitivity OR
specificity OR screen* OR preval* OR incidence) AND Topic=(dement* OR
alzheimer* OR cognitive OR cognition OR memory OR MCI OR petersen)
Databases=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH.
Lemmatization=On
 
6. LILACS (BIREME) to 20 May 2014
MMSE OR flostein OR "mini mental stat$" OR sMMSE OR MiniMental [Words]
 
7. ALOIS (CDCIG Specialized Register)
to 20 May 2014 [Search strategy run in
Medline (OvidSP) used to populate
ALOIS (Cochrane Dementia and
Cognitive Improvement specialized
register)]
1. "word recall".ti,ab.
2. ("7-minute screen" OR “seven-minute screen”).ti,ab.
3. ("6 item cognitive impairment test" OR “six-item cognitive impairment test”).ti,
ab.
4. "6 CIT".ti,ab.
5. "AB cognitive screen".ti,ab.
6. "abbreviated mental test".ti,ab.
7. "ADAS-cog".ti,ab.
8. AD8.ti,ab.
9. "inform* interview".ti,ab.
10. "animal fluency test".ti,ab.
11. "brief alzheimer* screen".ti,ab.
12. "brief cognitive scale".ti,ab.
13. "clinical dementia rating scale".ti,ab.
14. "clinical dementia test".ti,ab.
15. "community screening interview for dementia".ti,ab.
16. "cognitive abilities screening instrument".ti,ab.
17. "cognitive assessment screening test".ti,ab.
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18. "cognitive capacity screening examination".ti,ab.
19. "clock drawing test".ti,ab.
20. "deterioration cognitive observee".ti,ab.
21. ("Dem Tect" OR DemTect).ti,ab.
22. "object memory evaluation".ti,ab.
23. "IQCODE".ti,ab.
24. "mattis dementia rating scale".ti,ab.
25. "memory impairment screen".ti,ab.
26. "minnesota cognitive acuity screen".ti,ab.
27. "mini-cog".ti,ab.
28. "mini-mental state exam*".ti,ab.
29. "mmse".ti,ab.
30. "modified mini-mental state exam".ti,ab.
31. "3MS".ti,ab.
32. “neurobehavio?ral cognitive status exam*”.ti,ab.
33. "cognistat".ti,ab.
34. "quick cognitive screening test".ti,ab.
35. "QCST".ti,ab.
36. "rapid dementia screening test".ti,ab.
37. "RDST".ti,ab.
38. "repeatable battery for the assessment of neuropsychological status".ti,ab.
39. "RBANS".ti,ab.
40. "rowland universal dementia assessment scale".ti,ab.
41. "rudas".ti,ab.
42. "self-administered gerocognitive exam*".ti,ab.
43. ("self-administered" and "SAGE").ti,ab
44. "self-administered computerized screening test for dementia".ti,ab.
45. "short and sweet screening instrument".ti,ab.
46. "sassi".ti,ab.
47. "short cognitive performance test".ti,ab.
48. "syndrome kurztest".ti,ab.
49. ("six item screener" OR “6-item screener”).ti,ab.
50. "short memory questionnaire".ti,ab.
51. ("short memory questionnaire" and "SMQ").ti,ab.
52. "short orientation memory concentration test".ti,ab.
53. "s-omc".ti,ab.
54. "short blessed test".ti,ab.
55. "short portable mental status questionnaire".ti,ab.
56. "spmsq".ti,ab.
57. "short test of mental status".ti,ab.
58. "telephone interview of cognitive status modified".ti,ab.
59. "tics-m".ti,ab.
60. "trail making test".ti,ab.
61. "verbal fluency categories".ti,ab.
62. "WORLD test".ti,ab.
63. "general practitioner assessment of cognition".ti,ab.
64. "GPCOG".ti,ab.
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65. "Hopkins verbal learning test".ti,ab.
66. "HVLT".ti,ab.
67. "time and change test".ti,ab.
68. "modified world test".ti,ab.
69. "symptoms of dementia screener".ti,ab.
70. "dementia questionnaire".ti,ab.
71. "7MS".ti,ab.
72. ("concord informant dementia scale" or CIDS).ti,ab.
73. (SAPH or "dementia screening and perceived harm*").ti,ab.
74. or/1-73
75. exp Dementia/
76. Delirium, Dementia, Amnestic, Cognitive Disorders/
77. dement*.ti,ab.
78. alzheimer*.ti,ab.
79. AD.ti,ab.
80. ("lewy bod*" or DLB or LBD or FTD or FTLD or “frontotemporal lobar
degeneration” or “frontaltemporal dement*).ti,ab.
81. "cognit* impair*".ti,ab.
82. (cognit* adj4 (disorder* or declin* or fail* or function* or degenerat* or
deteriorat*)).ti,ab.
83. (memory adj3 (complain* or declin* or function* or disorder*)).ti,ab.
84. or/75-83
85. exp "sensitivity and specificity"/
86. "reproducibility of results"/
87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.
88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.
89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.
90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.
91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.
92. diagnos*.ti.
93. di.fs.
94. sensitivit*.ab.
95. specificit*.ab.
96. (ROC or "receiver operat*").ab.
97. Area under curve/
98. ("Area under curve" or AUC).ab.
99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
100. sROC.ab.
101. accura*.ti,ab.
102. (likelihood adj3 (ratio* or function*)).ab.
103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
104. ((true or false) adj3 (positive* or negative*)).ab.
105. ((positive* or negative* or false or true) adj3 rate*).ti,ab.
106. or/85-105
107. exp dementia/di
108. Cognition Disorders/di [Diagnosis]
109. Memory Disorders/di
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110. or/107-109
111. *Neuropsychological Tests/
112. *Questionnaires/
113. Geriatric Assessment/mt
114. *Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. "neuropsychological test*".ti,ab.
117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab.
118. (neuropsychological adj (assess* or evaluat* or test* or exam* or battery)).ti,
ab.
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122
124. 74 or 123
125. 110 and 124
126. 74 or 123
127. 84 and 106 and 126
128. 74 and 106
129. 125 or 127 or 128
130. exp Animals/ not Humans.sh.
131. 129 not 130
2 Information for extraction to proforma
Bibliographic details of primary paper.
Author, title of study, year and journal.
Details of index test.
Method of MMSE administration, including who administered and interpreted the test and their training.
Thresholds used to define positive and negative tests.
Reference standard.
Reference standard used.
Method of reference standard administration, including who administered the test and their training.
Study population.
Number of participants.
Age.
Gender.
Other characteristics (e.g. APOE status).
Settings: (i) community; (ii) primary care; (iii) secondary care outpatients; (iv) secondary care inpatients and residential
care.
Participant recruitment.
Sampling procedures.
Time between index test and reference standard.
Proportion of people in sample with dementia.
Subtype and stage of dementia if available.
MCI definition used (if applicable).
Duration of follow-up.
Attrition and missing data.
Results of the 2 × 2 tables cross-relating index test results of the reference standards.
Table 1: Conversion from MCI to Alzheimer’s disease dementia
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Index test
information
References standard information
ADD present ADD absent
Index test positive MMSE + who convert to ADD
(TP)
MMSE + who remain MCI (FP) & MMSE+ who convert to ADD (FP)
Index test negative MMSE - who convert to ADD (FN) MMSE - who remain MCI (TN) & MMSE- who convert to ADD (TN)
Table 2: Conversion from MCI to non-Alzheimer’s disease dementia
Index test
information
References standard information
Non-ADD present Non-ADD absent
Index test positive MMSE + who convert to non-ADD
(TP)
MMSE + who remain MCI (FP) & MMSE+ who convert to non-
ADD (FP)
Index test negative MMSE - who convert to non-ADD
(FN)
MMSE - who remain MCI (TN) & MMSE- who convert to non-ADD
(TN)
Table 3: Conversion from MCI to all-cause dementia
Index test informationReferences standard information
All-cause dementia present All-cause dementia absent
Index test positive MMSE + who convert to all-cause dementia (TP)MMSE + who remain MCI (FP)
Index test negative MMS - who convert to all-cause dementia (FN) MMSE - who remain MCI (TN)
3 Assessment of methodological quality QUADAS-2
Domain Patient selection Index test Reference standard Flow and timing
Description
 
Describe methods of
patient selection
Describe included
participants (prior
testing, presentation,
intended use of index
test and setting)
Describe the index test
and how it was
conducted and
interpreted
Describe the reference
standard and how it was
conducted and interpreted
 
Describe any participants who
did not receive the index test(s)
and/or reference standard or
who were excluded from the 2
× 2 table (refer to flow diagram)
Describe the time interval and
any interventions between
index test(s) and reference
standard
Signalling
questions
(yes, no,
unclear)
 
Was a consecutive or
random sample of
participants enrolled?
Was a case-control
design avoided?
Did the study avoid
inappropriate
exclusions?
 
Were the index test
results interpreted
without knowledge of
results of the reference
standard?
If a threshold was used,
was it prespecified?
 
Is the reference standard
likely to correctly classify
the target condition?
Were the reference
standard results
interpreted without
knowledge of results of the
index test?
 
Did all participants receive a
reference standard?
Did all participants receive the
same reference standard?
Were all participants included
in the analysis?
Risk of bias
(high, low,
unclear)
Could the selection of
participants have
introduced bias?
Could the conduct or
interpretation of the
index test have
introduced bias?
Could the reference
standard, its conduct or its
interpretation have
introduced bias?
Could the participant flow have
introduced bias?
Concerns
regarding
applicability
(high, low,
unclear)
Are there concerns that
included participants do
not match the review
question?
Are there concerns that
the index test, its
conduct or its
interpretation differs
from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
 
4 Anchoring statements for quality assessment of MMSE diagnostic studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy of MMSE. These statements
are designed for use with the QUADAS-2 tool and were derived during a 2-day, multidisciplinary focus group in 2010. If a
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QUADAS-2 signalling question for a specific domain is answered 'yes', then the risk of bias can be judged to be 'low'. If a
question is answered 'no', this indicates risk of potential bias.
The focus group was tasked with judging the extent of the bias for each domain. During this process, it became clear that
certain issues were key to assessing quality, whilst others were important to record but were less important for assessing
overall quality. To assist, we describe a 'weighting' system. When an item is weighted 'high risk', that section of the
QUADAS-2 results table is judged to have a high potential for bias if a signalling question is answered “no”. For example, in
dementia, diagnostic test accuracy studies, ensuring that clinicians performing dementia assessment are blinded to results of
the index test, are fundamental. If this blinding was not present, then the item on the reference standard should be scored
'high risk of bias', regardless of the other contributory elements. When an item is weighted 'low risk', it is judged to have a low
potential for bias if a signalling question for that section of the QUADAS-2 results table is answered 'no'. Overall bias will be
judged on whether other signalling questions (with a high risk of bias) for the same domain are also answered “no”. In
assessing individual items, the score of "unclear" should be given only if there is genuine uncertainty. In these situations,
review authors will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias? (high, low, unclear)
Was a consecutive or random sample of patients enrolled?
When sampling is used, the methods least likely to cause bias are consecutive sampling and random sampling, which should
be stated and/or described. Non-random sampling or sampling based on volunteers is more likely to be at high risk of bias.
Weighting: high risk of bias (no)
Was a case-control design avoided?
Case-control study designs have a high risk of bias, but sometimes they are the only studies available, especially if the index
test is expensive and/or invasive. Nested case-control designs (systematically selected from a defined population cohort) are
less prone to bias, but they will still narrow the spectrum of participants who receive the index test. Other study designs (both
cohort and case-control) that may increase bias are those designs for which the study team deliberately increases or
decreases the proportion of participants with the target condition, for example, a population study may be enriched with extra
participants with dementia from a secondary care setting.
Weighting: high risk of bias (no)
Did the study avoid inappropriate exclusions?
The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). When
exclusions are detailed, the study will be graded as “low risk” if exclusions are believed by the review authors to be
appropriate. Exclusions common to many studies of dementia include the following: medical instability; terminal disease;
alcohol/substance misuse; concomitant psychiatric diagnosis; and other neurodegenerative condition. However, if “difficult to
diagnose” groups are excluded, this may introduce bias, so exclusion criteria must be justified. For a community sample, we
would expect relatively few exclusions. Post hoc exclusions will be labelled “high risk” of bias.
Weighting: high risk of bias (no)
Applicability: are there concerns that included patients do not match the review question? (high, low, unclear)
Included patients should match the intended population as described in the review question. If not already specified in the
review inclusion criteria, the setting will be particularly important—the review authors should consider population in terms of
symptoms, pretesting and potential disease prevalence. Studies that use very selected participants or subgroups will be
classified as having low applicability, unless they are intended to represent a defined target population, for example, people
with memory problems referred to a specialist and investigated by lumbar puncture.
Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias? (high, low, unclear)
Were MMSE results interpreted without knowledge of the reference standard?
Terms such as “blinded” or “independently and without knowledge of” are sufficient, and full details of the blinding procedure
are not required. This item may be scored as “low risk” if explicitly described, or if a clear temporal pattern to the order of
testing precludes the need for formal blinding (e.g. all MMSE assessments were performed before the dementia
assessment). As most neuropsychological tests are administered by a third party, knowledge of the dementia diagnosis may
influence ratings; tests that are self-administered, for example, use of a computerised version, may be associated with less
risk of bias.
Weighting: high risk (no)
Were MMSE thresholds prespecified?
For neuropsychological scales, there is usually a threshold above which participants are classified as “test positive”; this may
be referred to as the threshold, the clinical cut-off or the dichotomisation point. Different thresholds are used in different
populations. A study is classified as having higher risk of bias if the study authors define the optimal cut-off post hoc on the
basis of their own study data. Some papers use an alternative methodology for analysis that does not use thresholds; these
papers should be classified as not applicable.
Weighting: high risk (no)
Were sufficient data on MMSE application given for the test to be repeated in an independent study?
DTA 20 Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people...
56 / 58
Particular points of interest include method of administration (e.g. self-completed questionnaire vs direct questioning
interview); nature of the informant; and language of the assessment. If a novel form of the index test is used, for example, a
translated questionnaire, details of the scale should be included and a reference given to an appropriate descriptive text;
evidence of validation should be provided.
Weighting: high risk (no)
Applicability: are there concerns that the index test, its conduct or its interpretation may differ from the review question?
(high, low, unclear)
Variations in length, structure, language and/or administration of the index test may affect applicability if they vary from those
specified in the review question.
Domain 3: reference standard
Risk of bias: could the reference standard, its conduct or its interpretation have introduced bias? (high, low, unclear)
Is the assessment used for clinical diagnosis of dementia acceptable?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and
ICD-10. Criteria specific to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s
dementia, McKeith criteria for Lewy body dementia, Lund-Manchester criteria for fronto-temporal dementia and NINDS-
AIREN criteria for vascular dementia. When the criteria used for assessment are not familiar to the review authors and the
Cochrane Dementia and Cognitive Improvement Group, this item should be classified as “high risk of bias”.
Weighting: high risk (no)
Was clinical assessment for dementia performed without knowledge of the MMSE results?
Terms such as “blinded” and “independent” are sufficient, and full details of the blinding procedure are not required.
Interpretation of results of the reference standard may be influenced by knowledge of results of the index test.
Weighting: high risk (no)
Applicability: are there concerns that the target condition as defined by the reference standard does not match the review
question? (high, low, unclear)
Some methods of dementia assessment, although valid, may diagnose a far smaller or larger proportion of individuals with
the disease than in usual clinical practise. For example, currently the reference standard for vascular dementia may
underdiagnose compared with usual clinical practise. In this instance, the item should be rated as having poor applicability.
Domain 4: participant flow and timing (note refer to, or construct, a flow diagram)
Risk of bias: could the participant flow have introduced bias? (high, low, unclear)
Was there an appropriate interval between MMSE and the reference standard?
As we test the accuracy of the MMSE test for MCI conversion to dementia, a delay will always be noted between the index
test and the reference standard assessments. The time between reference standard and index test will influence the
accuracy, and therefore we will note time as a separate variable (both within and between studies) and will test its influence
on diagnostic accuracy. We have set a minimum mean time to follow-up assessment of 1 year. If more than 16% of
participants undergo assessment for MCI conversion before 9 months, this item will score "no".
Weighting: high risk (no)
Did all participants receive the same reference standard?
In some scenarios, participants who score “test positive” on the index test may undergo a more detailed assessment for the
target condition. When dementia assessment (or reference standard) differs between participants, this should be classified
as high risk of bias.
Weighting: high risk (no)
Were all participants included in the final analysis?
If the number of participants enrolled differs from the number of participants included in the 2 × 2 table, the potential for bias
exists. If participants lost to follow-up differ systematically from those who remain, then estimates of test performance may
differ. If drop-outs are present, these should be accounted for; the maximum proportion of drop-outs for low risk of bias has
been specified as 20%. Details of the causes of study drop-outs are crucial, and if such data are missing, the reliability of the
conclusions must be questioned.
Weighting: high risk (no)
Graphs
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